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STAT3 IN EGF RECEPTOR MEDIATED FIBROBLASTS AND HUMAN PROSTATE 
CANCER CELLS MIGRATION AND INVASION AND APOPTOSIS 
Weixin Zhou, Ph.D. 
University of Pittsburgh, 2006
 
Growth factor-induced migration is a rate-limiting step in tumor invasiveness. The 
molecules that regulate this cellular behavior would represent novel targets for limiting tumor 
cell progression. Epidermal growth factor (EGF) receptor (EGFR)-mediated motility, present in 
both autocrine and paracrine modes in prostate carcinomas, requires de novo transcription to 
persist over times greater than a few hours. Therefore, we sought the specific signaling pathways 
that directly alter cellular transcription. We confirmed that STAT3 directly associates with, and 
is activated by EGFR in DU-145 and PC3 human prostate carcinoma cells in addition to the 
model NR6 fibroblast cell line. This correlated with electrophoretic motility shift of 
STAT3-selective oligonucleotides. Inhibition of STAT3 activity by antisense or siRNA 
down-regulation or expression of a dominant-negative construct limited cell motility as 
determined by an in vitro wound healing assay and invasiveness through a matrix barrier. The 
expression of constitutively activated STAT3 in the absence of EGF did not increase the 
migration. Together these data indicate that STAT3 is necessary but not sufficient for 
EGFR-mediated migration. An initial gene array detected a number of candidate operative 
molecules; the protein levels of both ENA/VASP, a repressor of cell motility, and caspase 3, a 
nexus of apoptotic signaling, were down regulated by EGF in a STAT3-dependent manner. 
Preliminary data show that EGF requires STAT3 functioning to inhibit the induction of apoptosis 
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in the two human prostate cancer cell lines. This suggests that STAT3 signaling may be 
contributing to tumor progression in a second manner by rendering the cells resistant to death. 
Together, the sum of these findings suggest that STAT3 signaling may be a new target for both 
limiting prostate tumor cell invasion and enabling the tumor cells to be killed.  
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1.0  INTRODUCTION 
Cancer progression results from complex and still riddling myriad of physiological and 
pathological events. Among them, the ability to break tissue and matrix barriers and establish 
growing masses within normal tissue represents the most fundamental characteristics of 
dissemination. Such spread causes the vast majority of morbidity and mortality from cancer.  
Histological analyses in de novo human tumor specimens and animal tumor models 
shows cancer cells invading into adjacent healthy tissues or breaching a basement membrane to 
access a vessel for dissemination; this local movement is termed tumor invasion [1]. The 
processes of invasion includes de-adhesion and penetration of surrounding matrix. Metastasis, 
which often has invasion as the first step, is the ability of the tumor cell to then move to, and 
grow in a new site. The difference between normal invasive growth and invasion is that normal 
cells end up with polarized structures while tumor cells infiltrate into surrounding tissue [2].  
 Central to invasion is the ability of the tumor cell to actively move into the surrounding 
matrix and tissue. Cell motility is tightly controlled by growth factors and cytokines during 
organogenesis, inflammation and wound healing, while it appears to become dysregulated during 
tumorgenesis. This lack of control and direction results in invasion. The initiation and 
maintenance of this aberrant motility is important to understanding the transition to tumor 
invasion [1]. 
 Many growth factors have had their increased levels in tumors correlated with tumor 
invasiveness [3]. As an example, EGFR signaling is upregulated in over half of the invasive 
gliomas compared to almost none of the non-invasive gliomas [4] [5]. EGFR is highly expressed 
in a variety of tumors including bladder, breast, colorectal, esophageal, gastric, head and neck, 
non-small cell lung cancer, ovarian, pancreatic and prostate cancers, and in most cases this 
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correlates with tumor invasion or metastasis [6]. How the EGFR signaling cascade works in 
those cells is the key to understanding metastasis and invasiveness of tumor cells.  
 
1.1 PROSTATE CANCER 
Adenocarcinoma of the prostate is the most common malignancy of the male genitourinary 
tract and is a significant health problem. In Europe the incidence of prostate cancer is 30 per 
100, 000 males, whilst in the USA rates of 178 per 100 000 have been reported [7]. This makes it 
the most common malignancy in American men. Localized prostate carcinomas exist in most of 
elderly males, but the most of those carcinomas are asymptomatic and medically important [8]. 
For this reason, the research of tumor proliferation and dissemination are even more important of 
this disease than of other cancers.  
 
1.1.1 Background of Prostate Cancer 
The major risk factors of prostate cancer including age, race, family history and maybe diet. 
The chance of getting prostate cancer is highly correlated with a man’s age. Most patients get 
prostate cancer when older than 55 [9] (Fig 1-1). Rates of prostate cancer vary widely across the 
world. It is least common in South and East Asia, more common in Europe and most common in 
the United States. In the United States, prostate cancer is more common in African American 
men than in white men. The chance of getting prostate cancer is also found related to family 
history [10]. Some studies suggest that dietary amounts of certain foods, vitamins, and minerals 
can also contribute to prostate cancer risk.  
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 Figure 1-1. Age distribution of deaths from prostate cancer in the United States. 
(From American Family Physician, Lefevre, 1998, modified) 
1.1.2 Diagnosis of Prostate Cancer 
The most commonly used method to diagnose and evaluate prostate cancer is the PSA 
(Prostate Specific Antigen) test though it is far from perfect. PSA is a serine protease produced 
by prostate, its normal function is to liquify gelatinous semen after ejaculation. The only test 
which can fully confirm the diagnosis of prostate cancer is a biopsy. 
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 Figure 1-2. Biopsy pictures of normal and prostate cancer tissue. 
Normal prostate (A) and prostate cancer (B). In prostate cancer, the regular glands of 
the normal prostate are replaced by irregular glands and clumps of cells. (From NIH website)  
1.1.3 Therapy of Prostate Cancer 
Treatment for prostate cancer includes but not limited to surgery, radiation therapy, 
cryosurgery and hormonal therapy. Surgical removal of the prostate (also called prostatectomy) 
is a common treatment mainly for early stage prostate cancer. Radiotherapy is also widely used 
in prostate cancer treatment. However, once the tumor has spread, such local tumor removal has 
little impact on the overall outcome or course of disease. Thus, the disseminated tumors need 
innovative and systemic approaches. 
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Hormonal therapy is to block prostate cancer cells from getting dihydrotestosterone 
(DHT) by medicine or surgery. DHT is a prostate produced hormone and is required for the 
growth and spread of most prostate cancer cells. Blocking DHT can inhibit prostate tumor 
growth. Early in the prostate carcinoma, such physical or chemical castration leads to regression 
of the tumor masses. However, this rarely cures prostate cancer as androgen independence 
develops within a year or two. Thus, we have focused on the tumor-intrinsic events, in 
androgen-independent prostate carcinomas, as novel approaches to halting the progression of this 
disease. 
 
1.1.4 EGFR mediated signalling pathway and Prostate Cancer 
EGFR plays a pivotal role in the metastasis and proliferation of prostate cancer cells. Local 
invasion leads to much morbidity and metastasis contributes most of the mortality in patients. It 
has been long known that tumors originating in different sites metastasize to different locations. 
Prostate cancer is usually clinically silent until metastatic disease produces symptoms. Prostate 
tumor cells metastasize preferentially to bone marrow, especially to bone in the central spine 
[11], and to the liver, though these are usually clinically silent [12] [13] [14]. The bone 
metastases, being osteogenic cause pain, and are often the earliest clinical signs of tumor spread 
[15] [16]. Prostate cancer is thought to spread by lymphatic and hematogenous vessels. The 
larger and less differentiated the primary tumor, the higher the incidence of metastases. The 
prostate cancer cells can spread to bone, lung liver, and kidney via blood vessels during the late 
stage of the disease.  
It is well known that growth factors stimulate the growth of tumors. In the case of 
prostate cancer, TGF-α was found to stimulate the cancer cell growth via the cell surface EGFR 
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[17] [18]. In the normal prostate stromal-derived TGF-α supports the prostate epithelium in a 
paracrine fashion. Both TGF-α and EGF are positive regulators for prostate cancer [19] [20], 
promoting growth and invasiveness. Several human prostate cancer cell lines, including PC3, 
DU145 and LNCaP cells, have autocrine loops consisting of EGFR and one or more of its 
ligands [21] [22]. The autocrine activation of EGFR by TGF-α and/or EGF promotes prostate 
tumor cell growth [23] [24] [25] and invasion and metastasis [26] [27]. 
 
 
1.2 EGF RECEPTOR AS A MOLECULAR IN SIGNALLING 
Epidermal growth factor or EGF is a growth factor that plays an important role in a lot of cell 
processes, which inclding growth, proliferation, migration, adhesion, apoptosis, angiogenesis and 
differentiation. Human EGF is a 6045 Daltons single chain protein with 53 amino acid residues 
derived from a large (1207 amino acids) integral membrane protein precursor [28]. EGF is the 
first described member of a family of related but distinct ligands that bind to the same receptor. 
Other members of this growth factor family which binds to EGFR include TGF-α 
(transformation growth factor α), HB-EGF, vaccinia growth factor, amphiregulin and neuregulin 
[29] [30] [31] [32] [33]. All of these ligands contain a conserved EGF-like domain and 
synthesized as transmembrane precursor proteins [34]. Those ligands, especially TGF-α, were 
found up regulated in many human cancers [35] [36] [37].  
Epidermal growth factor receptor or EGFR is a member of ErbB receptor family, a subfamily 
of four closely related receptor tyrosine kinases: EGFR (HER1 or ErbB-1), HER2/c-neu 
(ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4) [38]. EGFR is a 170 KDa transmembrane 
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glycoprotein with 1186 amino acids [39]. It has an extracellular domain with ligand binding sites 
and an intracellular domain with tyrosine kinase activity [40]; the other members of this family 
are similarly constructed. These receptors can homo- and hetero-dimerize to transmit signals 
(Figure 1.1). For instance HER2 has no known ligand and gets activated upon dimerizing with 
other members. HER3 does not have an active kinase domain, but rather serves to be 
phosphorylated by the other members of the EGFR family [41]. 
When the ligand binds to the EGFR, it induces a conformational change in the extracellular 
domain of EGFR and the receptor assembles into dimers. This greatly increases the EGF 
receptors’ intracellular tyrosine kinase activity. The activated EGFR kinase catalyses the transfer 
of the γ-phosphate of bound ATP to its own or the other’s C-terminal domain on specific 
tyrosine residues and also other substrates [42]. On activation, EGFR can pair with another 
EGFR to create a homodimer or pair with another member of the ErbB receptor family to form a 
heterodimer. Differences in the C-terminal domains of the ErbB receptors and the heterodimers 
they make results in different repertoires of signaling molecules that activated (Fig 1-1). There 
are also some compensating differences between the bindings of different ligands to EGFR [43]. 
The EGFR signaling affects apoptosis, differentiation, adhesion and, most evidently, cellular 
migration and proliferation [44]. 
Recent structural work shows that the activated EGFR is an asymmetrical dimer, with one 
kinase domain inducing allosteric activation of the other [45]. 
Various proteins can be complex with or phosphorylated by EGFR, which implies that 
EGFR activation can results in simultaneous activation of multiple pathways. The most well 
studied EGFR induced pathways include Ras/MAPK, STAT, and PLC-γ. Activated EGFR can 
bind to Grb2/Sos complex, which constitutively binds to Ras and resulting in the exchange of 
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Ras-bound GDP for GTP and hence Ras activation [46]. Activated Ras in turn activates Raf-1 
[47] and then Erk-1 and Erk-2. PLC-γ binds directly to the phosphorylated EGFR and is 
activated by it [48]. Activated PLC-γ then moves to the membrane and cleaves PIP2 
(phosphatidylinositol bisphosphate) into IP3 (inositol 1,3,5-trisphosphate) and DAG 
(1,2-diacylglycerol). This hydrolysis of PIP2 releases actin binding proteins that alter the 
cytoskeleton [49]. Further more, EGFR can also cross-talk with heterologous receptors activated 
by other inducers [50]. 
After performing its function, the EGFR signal is inactivated two ways. If the ligand comes 
off the receptor, phosphatases rapidly remove the phosphotyrosines which shuts off the kinase 
activity. The greater part of inactivation likely occurs through endocytosis of the receptor-ligand 
complex. The ligand binding receptor are then either degraded or recycled to the cell membrane 
again [38]. Among the other ErbB family receptors, HER2 attracts most of the attention from 
researchers. It is a major partner of EGFR in forming heterodimers [51]. Although HER2 is not a 
receptor for EGF, it decreases the rate of ligand dissociation from EGFR, [52] and activated 
heterodimers are more stable with HER2 in the complex [53]. This leads to prolonged and 
heightened signaling [54]. 
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Figure 1-3. Schematics of EGFR signalling pathway. 
A) Input level. The ligands and the dimerized receptors. Numbers indicate the respective 
high affinity HER receptor. HER1 (1), HER2 (2), HER3 (3) and HER4 (4). B) Signal 
transduction level. Not all the signalling pathways are shown here. C) Output level. Some target 
genes for EGFR signalling. (From The Oncologist, Arterga 2002) 
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 1.3 EGF RECEPTOR AND CANCER 
Aberrations in growth factor signaling pathways are strongly connected with cancer. 
Extracellular growth factors/growth factor receptors are essential for tumor invasiveness and 
metastasis as well as proliferation. The growth factor receptor most often found up-regulated in 
human tumors that have progressed to the invasive and metastatic state is the EGF receptor [55]. 
It is already demonstrated that the EGFR family of receptor tyrosine kinases lies at the beginning 
of many signal transduction pathways that regulate cell adhesion, migration, proliferation and 
differentiation [44]. Previous studies demonstrated that EGFR signaling in tumor cells causes 
enhanced motility/invasion, increased proliferation and decreased apoptosis, which are all critical 
to carcinogenesis.  
EGFR is found over expressed in many different solid human tumors, including 
non-small cell lung, breast, gastric, head and neck, bladder, ovarian, esophageal, glioblastomas, 
colorectal, pancreatic and prostate [56] [57] [58] .High EGFR expression correlates with severe 
tumor stage, higher invasiveness of the tumor cells [59], resistance to normal therapies [60] [61], 
and poor prognosis [62] [63] [64].  
The dysregulation of EGFR expression may come from mutations. A number of EGFR 
mutants have been found in tumors (Table 1) [65]. The most thoroughly studied EGFR mutant is 
EGFR vⅢ, in which exon 2-7 are missing. This truncated receptor has constitutive if low level 
activity and has defective downregulation [66] [67]. It has been detected in breast, 
medulloblastomas, and ovarian and non-small cell lung cancer [68]. 
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In addition to mutations, other mechanisms also cause aberrant EGFR regulation, such as 
ligand autocrine/over expression, hetero-dimerization with other ErbB receptors, especially 
HER2, and transactivation by heterologous signaling pathways. EGFR signals may be enhanced 
by high levels of ligands. Co-expression of EGFR and its ligands can result in activation of an 
autocrine loop which leading to dysregulation of EGFR [36] [69] [70]. 
During signal termination, activated EGFR is endocytosed. A ubiquitin ligase called Cbl 
is required in this process. EGFR homodimers are more stable in the mildly acidic endosomal 
environment and remain bound to Cbl, while EGFR-HER2 heterodimers are less stable and 
cause Cbl to dissociate from the receptor complex, and the receptor is not degraded [71] [72]. 
Many data show that cancers with high expression of both EGFR and HER2 have a worse 
prognosis than cancers that only have high expression of one of the receptors [73] [74] [75] [76]. 
Various methods have been applied to evaluate EGFR expression in human tumor and 
normal tissues. None of them is consistently employed in all the research groups and this making 
the comparison of results from different labs difficult. Some commonly used techniques 
including immunohistochemistry (IHC), Western, Northern, RT-PCR, fluorescence in situ 
hybridization and quantitative PCR.  
From decades of work, a variety of data supports the view that the EGFR is a relevant 
target for cancer therapy (Figure 1-2). So far, two main therapeutic approaches have been 
exploited to inhibit the EGFR. The first is the monoclonal antibodies that against EGFR [77] [78]. 
Those antibodies bind to the EGFR with affinity similar to normal EGFR ligands like EGF and 
TGF-α, compete with those ligands for receptor binding, and block EGF or TGF-α induced 
activation of EGFR tyrosine kinase. A second method targeting EGFR is the small molecular 
inhibitors of the EGFR tyrosine kinase enzymatic activity (TKIs) [79] [80]. Most of these 
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molecules are reversible competitors with ATP for binding to the intracellular catalytic domain 
of the tyrosine kinase.   
 
Type Alteration in sequence Reference 
EGFR vI Translation starts at aa 543 [81] 
EGFR vII Deletion of aa 521–603 [82] 
EGFR vIII Deletion of aa 6–273 [83] 
EGFR vIII/_12–13 Deletions of aa 6–273 and 409–520 [84] 
EGFR vIV Deletion of aa 959–1030 [85] 
EGFR vV Truncation at residue 958 [85] 
EGFR.TDM/2–7 Tandem duplication of 6–273 [86] 
EGFR.TDM/18–25 Tandem duplication of 664–1030 [86] 
EGFR.TDM/18–26 Tandem duplication of 664–1014 [87] 
 
Table 1. Mutations of the EGFR detected in tumor cells.  
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 Figure 1-4. EGFR signalling pathway and approaches to inhibiting the EGFR. 
Monoclonal antibodies against EGF receptor and small molecule inhibitors of tyrosine 
kinase are the two main groups that targeting the blockade of EGFR signalling pathway. (From 
Clinical Cancer Research, Ciardiello, 2001) 
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1.3.1 EGFR and Tumor Cell Invasion 
 Tumor invasion into surrounding tissues is the main reason for severe morbidity and 
mortality in many cancers, especially prostate, bladder, head and neck and esophagus [88]. 
Metastases cause 90% of human cancer deaths [89]. The removal of the primary tumors is 
accessible by surgery and radiological therapy, but local extension beyond the physiological 
borders can make patients impotent or engender adverse effects. The major events of metastasis 
include the invasion of adjacent tissues, intravasation, transport through the lymphatic and 
hematic system, arrest at a remote site and growth in a secondary organ (Figure 1-3) [90]. 
Early studies found that a number of retroviral oncogenes are derived from peptide growth 
factors and their receptors [88]. EGFR is the most frequently identified among those signaling 
molecules that over expressed in a wide variety of human tumor cells. Most epithelial cells 
express EGFR as well as its ligands like EGF and TGF-α. To prevent forming autocrine loop, the 
cells segregate the growth factors and their receptors by releasing them from different polarities 
[91] [92]. When the epithelium transformed with broken cell-cell junctions, the segregation 
disappears and results in autocrine stimulation [93]. Studies on different human tumor cells 
showed upregulated EGFR expression in invasive tumors compared to their non-invasive 
counterparts, which including glioblastomas, bladder and gastric carcinomas [4] [5] [94] [95]. 
For instance, ErbB2 is an important biomarker that is over expressed in 15-30% of human breast 
cancer and associated with poor prognosis [89]. More studies indicated that invasiveness of 
many tumor cells is modulated by EGFR mediated signals at least in vitro and in animal models 
[96] [26] [97] [98] [99].  
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 Figure 1-5. The invasive growth program under physiological and pathological 
conditions.  
Invasive growth results from dissociation and migration, cell multiplication and survival. 
Normal cells use invasive growth to colonize new territories and forming new organs in 
development while tumor cells forming metastasis. (From JCI, Comoglio, 2002) 
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A critical protein needed in the EGFR mediated migration is PLC-γ. Wells’ group 
demonstrated that overexpressing EGFR in DU145 human prostate carcinoma cells promoted 
EGF receptor dependent invasiveness both in vitro and in vivo [26] [27]. In addition, PLC-γ is 
necessary for the EGFR mediated motility [100] in human prostate tumor cells that over express 
EGF receptors. PLC-γ actuates motility by hydrolyzing PIP2 into IP3 (inositol 1,4,5-triphosphate) 
and DAG (diacylglycerol) and releasing actin binding proteins such as gelsolin, cofilin, and 
profilin [49] [101]. A second key switch for EGFR mediated motility is m-calpain. Activation of 
m-calpain is required for the deadhesion of tail retraction [102] [103]. How these molecules 
function in cell motility will be discussed below. 
 
1.3.2 EGFR and Tumor Cell Proliferation  
 It is well known that EGFR signaling is highly correlated with cell proliferation. The 
EGFR autocrine pathway contributes not only to cancer cell migration/metastasis, but also to 
proliferation, and decreased apoptosis [104]. In normal physiology, paracrine signaling of TGFα 
from fibroblasts to the endothelial cells promotes angiogenesis and to soft organ epithelial cells 
maintains the epithelial layer and heals any breaks. The aberrant activity of members of EGFR 
family has been shown to play a critical role in the cancer development and progression. EGFR 
combined with constitutive, elevated expression of c-myc leads to abrogated cell cycle regulation 
in an in vitro mammary epithelial cell model system [105]. The involvement of EGFR was 
recognized in breast cancer [106] [107], head and neck squamous cell carcinoma [108] [109], 
and prostate cancer [110].  
Normal cells require mitogenic growth signals for entering an active proliferative state. 
These signals are transmitted into the cell by transmembrane receptors that bind to distinctive 
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classes of signalling ligands. Dependence on growth signalling offers a strict control method to 
make cells only proliferate when in an appropriate environment. On the contrast, tumor cells 
generate many of their own growth signals, which greatly reduce the dependence on a normal 
tissue micro-environment and contribute to the unlimited growth of cancer cells. For instance, in 
human prostate tumor cells, a TGF-α/EGFR autocrine loop is built and thus liberating the tumor 
cells from normal growth regulation. 
 
1.4 SIGNALLING CELL MIGRATION INCLUDES ENA/VASP 
Directed cell migration is one of the most critical aspects of a functional living cell. It 
choreographs the morphogenesis of the embryo during development, and in adult cell migration 
is central to homeostatic processes such as immune response and the repair of injured tissues. 
The dysregulation of cell motility can cause tumor invasion, chronic inflammatory diseases, 
failure of wound healing and many other diseases [111] [112]. Cell migration is a dynamic, 
cyclical process (Figure 1-6). A cell first extends a protrusion at its front which attaches to the 
surface the cell is migrating, then moves the cell body forward toward the protrusion, and finally 
it releases the attachments at the cell rear as the cell continues to move forward [112]. 
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 Figure 1-6. Cell motility events.  
A schematic of the major steps involved in migration. (From Lauffenburge and Horowitz, 
1996 and modified). The various aspects of cell migration are listed and given with their mainly 
associated signaling molecules. First, a cell extends its lamellipods, and one of them becomes 
the main extension, which adheres to an adjacent surface. Secondly, a rearrangement of 
cytoskeleton happens, simultaneously with cellular morphological disruption and the flow of 
activated kinases towards the extension. Thirdly, the rear side of the cell contracts to the 
extension and is released from the surface. 
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1.4.1 Signalling Cell Migration 
Cell migration is initiated by external signals, which are recognized by specialized 
receptive proteins in the cell membrane. There are various signalling pathways and proteins 
involved in the process of cell migration from polarization to extension to rear release.  
EGFR signaling initiates migration in many cells. EGFR effects cell migration through 
numerous downstream signaling pathways. When EGFR get activated, it dimerizes and 
auto-phosphorylates the specific tyrosine residues that induce these pathways by binding via SH2 
domains [113]. The phosphorylated tyrosines on EGFR are recognized by the SH2 domains of 
PLC-γ and activate PLC-γ by phosphorylating it [114]. Activated PLC-γ then moves to the 
membrane [115] and cleaves PIP2 (phosphatidyl inositol 3,4-bisphosphate) into IP3 (inositol 
1,4,5-triphosphate) and DAG (diacylglycerol). When PIP2 is hydrolyzed, it releases many 
actin-binding proteins like gelsolin, cofilin, destrin, profiling and capping proteins from 
inhibition [116] [117] [118] [119] and thus making them available for the cytoskeletal 
reorganization and protrusion formation [49]. On the other hand, DAG can signal for PKC 
activation, which downregulates EGFR activity while IP3 signaling releases Ca2+ from 
endoplasmic reticulum leading to the activation of Ca2+- dependent enzymes like PKC and 
μ-calpain.  
Another pathway from EGFR for cell migration is through ERK/MARK [120]. EGF 
signaling goes through Ras-Raf-MEK-MAPK/ERK and the last activates m-calpain by 
phosphorylating its Ser50 [121] [122]. Calpains are a family of calcium-dependent intracellular 
cysteine proseases. They cleave several substrate proteins that connect the cytoskeleton to the 
substratum [123] [124] [125] [126] [127] [128] [129], which demonstrates this pathway is 
required for focal adhesion disassembly and decrease in adhesiveness to the substratum. [102]  
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Figure 1-7. EGFR mediated cell motility pathways.  
A schematics of EGFR mediated pathways regulating cell migration. EGF receptors 
phosphorylate PLC-γ and PI3K. Only surface EGF receptors mediate PIP2 hydrolysis by PLC 
because PIP2 is not accessible to internalized receptors.  
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As we just mentioned, PLC-γ activation by EGFR produces DAG, which activates the 
Ser/Thr kinase protein kinase C (PKC). PKC is a large family of at least 12 members [130]. PKC  
proteins phosphorylate a variety of substrates including signal transductional proteins [131] and 
motility-associated proteins [132] [133], making PKC an important player in migration signaling 
pathways. Increased levels of PKC have been found associated with malignant transformation in 
a number of cancers including lung, breast and gastric carcinomas. Previous work in our lab 
clarified the EGF induced signaling pathway of migration in fibroblast cells. We demonstrated 
that EGF stimulation increases myosin light chain (MLC) phosphorylation, which is a marker for 
contractile force, concomitant with protein kinase C, particularly PKCδ [134]. Many recent data 
suggest a crucial role that PKCδ may plays in breast cancer [135] [136], both for its invasion and 
proliferation [137]. One of the interesting characteristics of PKC is that PKC attenuates signaling 
from the EGF receptor [138]. It decreases the binding affinity of the EGFR and its ligands [139] 
and diminishes tyrosine kinase activity of the receptor [140]. These data imply a feedback 
attenuation mechanism in the EGFR induced cell migration regulation [141].  
Lamellipod extension is the most obvious process in cell motility. This protrusion 
extends from the cell body to create new, distal adhesion sites. The leading edge of a lamillipod 
contains highly branched actin filaments [142]. At the leading edge, G-actin monomers are 
added to the barbed ends of actin filaments and removed from the pointed end [143], which 
pushes the membrane forward and leads to protursion at the leading edge. This cytoskeletal 
growth is made possible by actin binding proteins released by PIP2 hydrolysis by PLC-γ. How 
these are presented at the front of the cell, even in the absence of a gradient, involves Cdc42 
binding to PLC-γ and directing towards the leading edge [144]. This then denudes the front of 
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PIP2. As m-calpain needs PIP2 to be fully activated by EGFR, this asymmetry of PLC-γ results in 
de-adhesion occurring only at the cell’s rear [145]. 
  
 
1.4.2 Arp2/3 Complex 
The polarizing of actin in the lamellipod is regulated by proteins that bind to and modify 
actin. Arp2/3 (Actin-related protein 2/3) is a stable protein complex that responsible for 
branching [146] and nucleation [147] of actin filaments. It is localized to the leading protrusions 
of migrating cells [148] [149]. After being activated by WASPs (Wiskott-Aldrich Syndrome 
proteins), Arp2/3 nucleates actin by binding profilin, a protein bound to monomeric actin-ATP 
[150]. The actin-ATP is transported to the nucleated actin on Arp2/3, then loses its γ-phosphate 
group and becomes actin-ADP. The Arp2/3 complex caps the pointed ends of actin filaments, 
this is the molecular basis for the formation of highly branched actin filament network at the 
leading edge [151]. Most recent data demonstrated that mRNAs for the seven subunits of Arp2/3 
complex are localized to the protrusions in fibroblasts, which supporting the hypothesis that 
Arp2/3 is targeted to its function site by mRNA localization [152].  
 
1.4.3 Ena/VASP 
Ena/VASP Proteins are actin-binding proteins that localize to actin stress fibres, 
filopodial tips and to the lamellipodial leading edge [153]. Enabled (Ena) was first found in 1990 
as a genetic suppressor of mutations in Drosophila Ableson tyrosine kinase [154]. Ena was also 
found to function in several signaling pathways essential for axon guidance in the developing of 
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nervous system [155] [156]. Vertebrates have the other three members in this family, which are 
VASP (Vasodilator-stimulated phosphoprotein), Mena (Mammalian Enabled) and EVL 
(Ena-VASP like). They localize to focal adhesions, actin stress fibers, filopodial tips and 
lamellipodial leading edge [157] [158] [159]. VASP was also identified as a major protein kinase 
A substrate in platelets [160]. Ena/VASP family members share a conserved domain structure 
consisting of an N-terminal Ena-VASP-homology-1 (EVH1) domain, a central polyproline-rich 
core and a C-terminal EVH2 domain (Fig 1-9).  
The studies on Ena/VASP these years got a number of seemingly conflict results. 
Deletion of the Ena/VASP binding sites within the bacterial protein ActA decreased actin 
dependent intracellular motility [161] [162], delocalization of all Ena/VASP proteins abolished 
reorganization of the actin cytoskeleton and impaired actin dependent phagocytosis [163] [164], 
and purified Ena/VASP proteins can stimulate the nucleation of actin filaments in vitro [165] 
[166] [167]. This was all interpreted as indications of a positive role for Ena/VASP in actin 
dependent process. On the other side, a dose-dependent decrease in movement is observed when 
Ena/VASP proteins are over expressed in fibroblasts and deletion of them results in increased 
cell movement [168]. Platelets without VASP expression shows increased collagen induced 
platelet aggregation [169]. Neutralization of Ena/VASP functions in neurons in the developing 
neocortex leads them migrate much farther than normal neurons [170]. All these data suggest a 
negative role for Ena/VASP proteins in actin dependent processes.  
Although all those processes mentioned are actin dependent, they are not directly 
comparable. There is no persuasive evidence supporting Ena/VASP as nucleator of actin in 
living cells [171]. Recent study shows Ena/VASP proteins antagonize capping protein to inhibit 
actin polymerization at barbed ends in vitro [172], which suggested that Ena/VASP proteins 
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associate with actin filaments at or near the barbed end and protect them from being capped by 
capping protein. The depletion of Ena/VASP making the lamellipodial protrudes slower but 
persists longer, which actually makes cells move faster (Fig 1-9). 
 
 
 
 
Figure 1-8. Domain structure of Ena/VASP family proteins. 
Primary structure of Ena/VASP family proteins with their binding partners and functions. 
(From: Krause M. et al. 2002 J Cell Sci) 
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 Figure 1-9. Antagonism between Ena/VASP and capping protein. 
The antagonism between Ena/VASP and capping protein regulates lamellipodial 
protrusion and whole cell motility. Elevated Ena/VASP activity inhibits capping protein in the 
leading edge, resulting in longer and less branched actin filaments. This leads to higher 
lamellipodial protrusion velocity but shortened persistence. (From JCS, Krause, 2002) 
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1.4.4 Regulation of β-actin 
Cells may also modulate migration by regulating localization of β-actin messenger RNA to 
sites of active actin polymerization [173] [174] [175]. This monomer is the building block of the 
actin cytoskeleton, and supply of the monomer regulates actin filament length and extension. 
Asymmetric localization of specific mRNAs generates cell polarity by controlling sites of 
translation and restricting the synthesis of its protein product to specific compartments of the cell 
[176] [177]. β-actin mRNA is localized near the leading edge where actin polymerization is 
actively promoting forward protrusion. A protein called ZBP1 (Zipcode binding protein 1) is 
necessary for the localization. This protein binds to a conserved 54-nucleotide element in the 
3’-untranslated region of β-actin mRNA known as “zipcode”. [178] [179] The β-actin zipcode 
sequence is essential for correct targeting of β-actin mRNA [180]. The mRNAs are transported 
on microtubules and actin filaments and anchored on actin filaments [181] [182] [183]. Most 
recent research found ZBP1 associates with the β-actin transcript in the nucleus and blocks 
initiation of translation in cytoplasm until the ZBP1-mRNA complex reaches its destination, 
where the protein kinase Src phosphorylates a tyrosine residue in ZBP1 that is required for 
binding to RNA and promotes translation [184] (Fig 1-11). 
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 Figure 1-10. Regulation of localized β-actin mRNA translation in a polarized neural cell. 
ZBP1 protein is regarded to control the transport of β-actin mRNA and its translation. 
ZBP1 escorts β-actin mRNA from nucleus to the cytoplasm, at where the ZBP1-β-actin mRNA 
complex binds to a motor protein and is transported along the cytoskeleton to the periphery. 
During transport, ZBP1 prevents the mRNA from being translated. (From Nature, Dahm, 2005) 
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1.5 SIGNAL TRANSDUCERS AND ACTIVATORS OF TRANSCRIPTION 
One of the major signal transduction pathways required for proliferation and migration 
mediated by EGFR is the activation and translocation of STATs [185] [186]. De novo 
transcription is required for proliferation, and also for migration [100]. It is still unknown 
whether the transcriptional need in migration is for replacement of degraded proteins, increased 
levels of the motility machinery components, or specific regulatory factors. Therefore, I decided 
to ask whether this key transcriptional pathway was required in prostate cancer motility. 
EGFR was found to directly activate STAT 1, STAT 3 and STAT 5. Our lab was among the 
first to demonstrate that EGFR activates members of the STAT family [187]. Activation of ERK 
MAP kinases and PI3-kinase are not sufficient for mitogenesis by growth factors, suggesting that 
an additional pathway such as STAT is needed [188]. 
 
1.5.1 Background of STATs 
STAT (Signal Transducer and Activator of Transcription) is a family of transcription factors 
that are implicated in programming gene expression in biological events, including embryonic 
development, programmed cell death, organogenesis, innate immunity, adaptive immunity and 
cell growth regulation [189]. Seven mammalian STAT genes have been found now; they are 
STAT1, 2, 3, 4, 5a, 5b and 6, which are structurally conserved (Fig 1-12). All the seven members 
of the STAT family share several conserved domains. Those domains including an 
amino-terminal domain (interacts with the transcriptional co-activator and regulates nuclear 
translocation); a coiled-coil domain (forming predominantly hydrophilic surface, receptor 
binding, tyrosine phosphorylation and nuclear export); the DNA binding domain; a linker 
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domain; an SH2 domain (binds to specific phospho-tyrosine motifs); a tyrosine activation 
domain (circled P) and the transcriptional activation domain. The transcriptional activation 
domain (TAD) is conserved in function but not in sequence [190].  
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Figure 1-11. STAT structure and family of proteins. 
The domain structure of the seven STAT family members is shown. The N-terminal 
domain mediates the interaction between two STAT dimers to form a tetramer. The coiled-coil 
domain is involved in interactions with regulatory proteins and other transcription factors. The 
DNA binding domain makes direct contact with STAT-binding sites in gene promoters with 
consensus core sequence. Reciprocal interaction of SH2 domain of one STAT monomer and the 
phosphotyrosine of another mediate dimer formation. (Nature Reviews of Cancer, Jove 2004) 
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1.5.2 Signalling Pathways that activate STATs 
The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway 
transmits information received from extracellular polypeptide growth factors, through 
transmembrane receptors, directly to target gene promoters in the nucleus, providing a 
mechanism for transcriptional regulation without second messengers [191]. The STAT signaling 
pathways were originally found in the cascade of normal cytokine receptors like interferon (IFN) 
and interleukin-6 (IL-6). Unlike growth factor receptors, most of the cytokine receptors are 
devoid of intrinsic tyrosine kinase activity. Instead, ligand engagement leads to activation of 
Janus kinase (JAK) family members, a group of receptor associated tyrosine kinases [192]. In 
some cases, SRC family kinases also involved [193]. Those kinases phosphorylate specific 
tyrosine residues on the cytoplasmic tails of cytokine receptors, thus providing docking sites for 
STAT monomer’s SH2 (SRC Homology 2) domain. The recruited STAT monomers are 
phosphorylated on their specific tyrosine residues by the JAK or SRC kinases and form activated 
dimers through reciprocal phosphotyrosine-SH2 interactions between two monomers [192]. 
STATs can be activated by growth factor receptors with intrinsic tyrosine kinase activity. 
Those receptors include EGFR and PDGFR (platelet derived growth factor receptor) [194] [195]. 
These activate STAT directly without the intervention of JAK kinases [196]. However, the 
intrinsic tyrosine kinases also may cooperate with JAK kinases in the phosphorylation of STATs 
[197]. There is also non-receptor, cytoplasmic tyrosine kinases that signal through STATs, which 
include ABL (Abelson Leukaemia Protein) and SRC related kinases (Fig 1-13) [198]. 
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 Figure 1-12. Signalling pathways of STATs.  
Binding of growth factors or cytokines to their receptors results in the activation of 
intracellular receptor tyrosine kinase activity or receptor associated kinases such as JAK or SRC. 
These activated tyrosine kinases phosphorylate the receptor tails that in the cytoplasm, which 
provide a docking sites for the mono-STAT protein. Non-receptor tyrosine kinases, such as ABL, 
can phosphorylate STATs withorht receptor engagement. After been recruited, STAT monomers 
phosphorylate each other on special tyrosine residues and form activated dimers. The dimers 
translocate to the nucleus and directly regulate gene expression. (From Nature Reviews of 
Cancer, Jove, 2004 and modified)  
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1.5.3 STAT3 and Cancer 
In many cancer cells, both cytokine and growth factor receptors become constitutively 
active due to autocrine or paracrine expression of their own ligands, mutations, failure of 
degradation or simply over expression of themselves. These aberrant changes can all cause the 
constitutive activation of STATs.  
STAT3 activation is implicated in tumor invasion in head and neck squamous cell and 
other carcinomas [185] [186]. A significant correlation has been reported between the expression 
of nuclear STAT3 and breast cancer as compared to normal mammary tissues [199]. 
Interestingly, prostate tumor cells have been found to contain constitutively activated STAT3, 
and blockade of this activated STAT3 significantly suppressing the tumor cell growth [200] [201] 
[202]. A first clue implicating STATs in oncogenesis was the finding that STAT3 is 
constitutively activated in SRC transformed cell lines and interrupting STAT3 signaling blocks 
the transformation [203] [204] [205]. This is of key interest as a later study demonstrated that 
constitutively activated STAT3 mediate cellular transformation [206]. A survey of 
organ-confined prostate biopsies demonstrated a correlation between local aggressiveness and 
phospho-STAT3 staining [207]. These reports support hypothesizing that STAT3 signaling 
contributes to carcinogenic progression, in addition to increasing the cell number.   
Constitutively activated STAT3 has been detected at high frequency in many human 
cancers (Table 2). Various signaling molecules and their receptors like IL-6, TGF-α, EGF and 
HGF (Hepatocyte Growth Factor) are involved in this process. Besides being a crucial part for a 
variety of oncogenic signaling pathway, STAT3 also participates in tumor cell growth, survival, 
angiogenesis and immune evasion. The first direct evidence that inhibition of STAT3 signaling 
in human cancer cells apoptosis came from the finding that increased expression of BCL-XL, an 
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anti-apoptotic BCL-2 family gene, is dependent on constitutively activated STAT3 [208]. More 
research data demonstrated that activated STAT3 increases the expression of c-Myc and cyclin 
D1, which are both critical to cell proliferation and suppress the expression of TP53 gene, the 
inducer of apoptosis [206] [209]. The same group also found STAT3 is a direct transcriptional 
activator of the VEGF (Vascular Endothelial Growth Factor) gene. Blocking STAT3 signaling 
inhibits the SRC and IL-6 induced VEGF up regulation [210]. Furthermore, inhibition of STAT3 
in tumor cells was found to lead the production of inflammatory cytokines and chemokines, 
which in turn activate immune cells [211]. 
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TUMOR TYPE 
SOLID TUMORS 
ACTIVATED STAT 
PROTEIN 
REFERENCE 
Breast cancer STAT1, 3, 5 [212] 
Head and neck cancer STAT1, 3, 5 [186] 
Melanoma STAT3 [213] 
Lung cancer STAT3, 5 [214] 
Ovarian cancer STAT3 [215] 
Pancreatic cancer STAT3 [216] 
Prostate cancer STAT3, 5 [217] 
BLOOD TUMORS   
Multiple myeloma STAT1, 3 [218] 
HTLV-1-dependent leukemia STAT3, 5 [219] 
Acute myelogenous leukemia STAT1, 3, 5 [220] 
Chronic myelogenous leukemia STAT5 [221] 
Large-granular-lymphocyte leukemia STAT3 [222] 
Acute lymphoblastic leukemia STAT5 [223] 
LYMPHOMA   
EBV-related and Burkitt's lymphoma STAT3 [224] 
Cutaneous T-cell lymphoma STAT3 [225] 
B-cell non-Hodgkin's lymphoma STAT6 [226] 
Anaplastic large-cell lymphoma STAT3 [227] 
 
Table 2. Activation of STATs in human cancers. 
 
 
1.6 CASPASES AND APOPTOSIS 
Apoptosis is a programmed form of cell death, which is regulated in an orderly way by signal 
pathways under certain situations. Apoptosis is critical to cell growth regulation, development, 
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immune response as well as keeping a constant amount of cells for organs. A hallmark of cancers 
is the imbalance between cell proliferation and death, mainly by apoptosis, resulting in excessive 
cell number. For the slow growing prostate cancer, there is often more a deficit of apoptosis 
rather than rapid proliferation.  
 
1.6.1 Apoptosis 
So far, there are two main apoptosis pathways have been described: the death receptor 
induced pathway and the mitochondrial mediated pathway, or called extrinsic and intrinsic 
pathway according to the location of initial signaling [90]. Both of these pathways activate the 
executioner intracellular proteases, caspases.  
Generally, there are two pathways for caspase proteins to be activated: one is the death signal 
induced and the other is mitochondrion mediated. In the first pathway, death signals as TNF 
(tumor necrosis factor) or FasL can be specifically recognized by their receptors and activate 
those receptors. Activated death receptors will interact with pro-caspases and induce their 
activation through oligomerization and auto-cleavage, leading to apoptosis [228]. On the other 
hand, procaspase can also be activated through a cytochrome C dependent pathway. After 
cytochrome C is released from mitochondria under cellular stress like DNA damage, it can 
directly activate some type of procaspase or form a complex called the apoptosome by 
oligomerizing Apaf-1 (apoptotic protease activation factor-1), then activate caspases [229] [230]. 
There are many regulators of mitochondria mediated apoptosis pathway, including BCL-2 and 
BCL-XL, which negative to apoptosis; and BAX and BAD, which is pro-apoptosis (Fig 1-14). 
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 Figure 1-13. Schematic representing the core components of apoptosis pathways.  
In the extrinsic pathway, TNF super family members including Fas Ligands binding to a 
death receptor and forming a death inducing signalling complex (DISC), which activate 
caspase-8. In the intrinsic pathway, cytochrome c released from mitochondria causes 
apoptosome formation and caspase-9 activation. Both caspase-8 and caspase-9 activate down 
stream caspases like caspase-3 and leading to apoptosis. (From Patric, 2006 and modified) 
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1.6.2 Caspase proteins 
The initiation and execution of apoptosis requires a group of proteins that include signal 
transducers, receptors, gene regulators and enzymes. Among them, the caspase proteins are vital 
to the process of apoptosis [231]. 
Fourteen members of caspase family have been identified up to now, and all share some 
common properties. Caspases are aspartate-specific cysteine proteases and they all come from a 
zymogen precursor. Based on their function and homology in amino acid sequences, caspases are 
divided into three groups: apoptosis activators like caspase 2, 8, 9, 10 that contain a long 
prodomain at the N-terminus; apoptosis executioners such as caspase 3, 6, 7 that have a short 
prodomain and inflammatory mediators with caspase 1, 4, 5, 11, 12, 13 and 14 (Table 3). 
Among all the apoptosis-related caspase proteins, Caspase 3 acts at the effector’s stage of the 
whole signal cascade. It cleaves various of targets like PARP (poly ADP-ribose polymerase) and 
DFF (DNA fragmentation factor) that lead to cell death as well as cleaving Caspase 6, Caspase 7 
and caspase 9 [232]. Also known as CPP32, Yama or apopain, Caspase 3 is a key factor in 
apoptosis execution. It is activated by cleavage from procaspase 3. It was found that a small 
molecule antagonists of XIAP (X-chromosome-linked inhibitor of apoptosis protein) that 
overcome inhibition of caspase-3 directly induced cell death in tumor cells while having little 
toxicity on normal cells, which indicates a critical role of caspase-3 in cancer cell apoptosis 
[233]. 
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 Subfamily Role Members 
I Apoptosis activator Caspase-2 
  Caspase-8 
  Caspase-9 
  Caspase-10 
II Apoptosis executioner Caspase-3 
  Caspase-6 
  Caspase-7 
III Inflammatory mediator Caspase-1 
  Caspase-4 
  Caspase-5 
  Caspase-11 
  Caspase-12 
  Caspase-13 
  Caspase-14 
 
Table 3. Subfamily of caspase proteins. 
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2.0  MATERIAL AND METHODS 
 
2.1 CELL LINES & MEDIUM 
A murine fibroblast line was selected to define the transcriptional changes concomitant 
with EGFR-mediated cell motility. This was chosen as such fibroblast lines avoid the autocrine 
signaling through EGFR that is prevalent in carcinoma cells including those of the prostate [234]. 
The line chosen is a well characterized subline of NR6 cells that now expresses physiological 
levels of the EGFR [235]. These are derived from murine Balb/c 3T3 cells that were selected to 
not respond to EGF; these cells had silenced their EGFR transcription [236]. EGFR was 
expressed upon MLV-based retroviral transduction of a single gene copy with the selectable 
marker, neomycin phosphotransferase, driven from the env position using a separate promoter. 
Use of these cells allowed for isolation of EGFR signaling by comparison to the parental NR6 
cells. 
I chose to use two human prostate carcinoma cell lines to explore the role of the 
STAT3-driven transcription changes in tumor progression and survival. Androgen-independent 
cell lines were used as these represent the state at which prostate carcinoma is refractory to 
standard hormonal therapy [237] [238] and the situation that engenders the major part of prostate 
cancer mortality [239]. DU145 cells were selected as their in vitro and in vivo invasive behavior 
is well characterized [26] [27]. These were derived from a prostate adenocarcinoma metastasis to 
the brain [238]. These cells are only moderately invasive and have limited dissemination from 
orthotropic (intra-prostate) inoculation in mice. These cells were made more invasive and 
metastatic by over expression of full length human EGFR [26] [27]. DU145 present a mutant 
androgen receptor that is independent of exogenous testosterone [240]. The second cell line, 
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PC-3, was isolated from a prostate adenocarcinoma metastasis to the bone [237]. This line is 
considered highly aggressive and metastatic when inoculated in mice.   
Human DU145 prostate carcinoma cells [238] over-expressing EGFR, DU145WT [26], 
were maintained in Dulbecco’s minimal essential media (DMEM) (Mediatech) supplemented 
with 10% fetal bovine sera (FBS), L-glutamine (2mM), non-essential amino acids (0.1mM), 
sodium pyruvate (1mM) and 100U/ml of penicillin. To maintain expression from the transduced 
EGFR in the DU145WT cells, 350 mg/ml of G418 was added to the media. Human PC3 prostate 
cancer cells [237] were maintained in F-12 medium (GIBCO) supplemented with 10% FBS, 
L-glutamine (2mM), non-essential amino acids (0.1mM), and sodium pyruvate (1mM). NR6WT 
mouse fibroblasts expressing human EGFR [235] were maintained in Eagle’s minimal essential 
medium alpha modification (MEMα) (Mediatech) supplemented with 10% FBS, L-glutamine 
(2mM), non-essential amino acids (0.1mM), sodium pyruvate (1mM), 100 U/ml of penicillin and 
350 mg/ml of G418. All the cells were grown in 5% CO2 at 37˚C.  
 
2.2 RNA PURIFICATION  
To purify the RNA for microarray analyses, the treated cells were washed by ice cold 1 X 
PBS twice. 1 ml of Trizol was added into each 10 cm plate and incubated at room temperature 
for 5 minutes. After incubation, the cells were scraped and transferred into a 1.5 ml centrifugal 
tube. Chloroform equal to 20% of the original volume of cells was added into the tube and shake 
vigorously by hand for 15 seconds. The mixture was incubated at room temperature for 2 
minutes before going centrifuge at 12,000 rpm for 15 minutes. The upper aqueous after 
centrifuge was transferred into a fresh tube and 75% of the volume of isopropyl alcohol was 
added. The mixture was incubated at room temperature for at least 10 minutes before going 
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centrifuge again at 12,000 rpm for 15 minutes. The pellets were washed with 70% and then 
100% ethanol, ended with air dry for 10 minutes [241].   
 
2.3 MICROARRAY ANALYSES 
To determine the genes transcribed downstream from EGFR/STAT3 signaling pathway, 
we performed transcription microarray analyses to monitor the gene expression changes in RNA 
levels. The experimental design was to determine which transcripts were both up after EGF 
exposure and then reverted to untreated levels when the cells were treated with STAT3 antisense 
oligonucleotides prior to EGF treatment. I chose the NR6WT fibroblast cell, which expresses 
physiological levels of the EGFR [235]. Use of these cells allowed for isolation of EGFR 
signaling from the confounding influence of growth factors and their receptors’ autocrine loops 
in human prostate tumor cell lines.  
The NR6WT cells were starved in MEMα media containing 0.5% FBS for 24 hours to 
quiescent the cells before treatment with 1nM of EGF and/or 10µM of mouse STAT3 antisense 
nucleotide for another 24 hours. The sequence of it is 5’-GTT CCA CTG AGC CAT CCT GC-3’. 
After the treatment, the RNA from those cells was purified with the protocol described in above. 
5μg RNA from each sample was prepared for microarray analysis using the Affymetrix U74AV2 
murine genome array chip that contains probe sets interrogating approximately 36,000 
full-length mouse genes and EST clusters from the UniGene database of transcripts. 5 μg of 
purified total RNA were added into a 20 μl first strand reaction with 200 U of SuperScript II 
(Invitrogen) and 1 µg T7 primer [5’-GGCCAGTGAATTGTAATACGACTCACTATAGGGAG 
GCGG(T)24] in 1X first strand buffer (Invitrogen) followed by a 42°C incubation for 1 hour. 
Second strand synthesis was performed by adding 40 U of E. coli DNA polymerase, 2 U of E. 
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coli RNase H, and 10 U of E. coli DNA Ligase in 1 X second strand buffer followed by 
incubation at 16°C for 2 hrs. The second strand synthesis reaction was purified according to the 
manufacturer’s protocol (Affymetrix). The purified cDNA was amplified according to 
manufacturer’s protocol to produce 70-120 μg of biotin labeled cRNA [242]. 
Murine U74Av2 GeneChip probe arrays were pre-hybridized in a GeneChip 
Hybridization Oven 640 (Affymetrix) according to the manufacturer’s protocol. 15 μg of labeled 
cRNA were fragmented in 30 μl 1X fragmentation buffer with 100 mM KOAc and 30 mM 
MgOAc at 95°C for 35 minutes. The fragmented labeled cRNA was resuspended in 300 μl 1X 
hybridization buffer containing 100 mM MES, 1 M [Na+], 20 mM EDTA, 0.01% Tween 20, 0.5 
mg/mL Aceylated BSA, 0.1 mg/ml herring sperm DNA, control oligonucleotide B2, and control 
transcripts bioB 1.5 pM, bioC 5 pM, bioD 25 pM, and cre 100 pM. 200 μl of the hybridization 
cocktail (containing 10 μg of labeled cRNA) were hybridized to GeneChip probe arrays 
according to manufacturer’s protocol (Affymetrix). 
The raw data from microarray were normalized with the Affymetrix Microarray suite 5.0, 
based on the housekeeping gene expression profile. Expression values were adjusted to the 
intensity of the expression value of the 100 housekeeping genes. This allowed us to normalize 
between runs.  
  
2.4 MOLECULAR CLONING  
To check if STAT3 effects alone are sufficient for EGFR mediated cell migration, I used a 
constitutively activated STAT3 mutant to transfect the NR6WT cells. A dominant negative 
mutant of STAT3 and empty vector were used as controls. In Stat3D, E434 and E435 of Stat3, 
 43 
which is in the DNA binding domain, were replaced with alanines [243]. This construct 
competes for upstream activation signals but cannot promote transcription [244] [245]. The 
constitutively active mutant [206] of STAT3 was generated by a mutation of substituting 
cysteine residues for A661 and N663 of the Stat3 molecule, which allowed for sulfhydryl bonds 
to form between STAT3 monomers and render a STAT3 that dimerizes independent of upstream 
activation [206]. Both constructs were kindly provided to me by Dr. Jennifer Grandis. The 
mutant fragments were cut by Not I and Hind III endonucleases and inserted into pCEP4-MMTV 
expression plasmid that induced by dexamethasone and has hygromycin resistance [246]. The 
cloning was checked by DNA sequencing and immunoblot for the expression marker of HA-tag 
in dominant negative STAT3 and Flag in constitutively active STAT3 mutants. 
 
2.5 ELECTROPORATION AND SELECTION OF THE CLONS 
The constructed plasmid with STAT3 mutants were transfected into NR6WT cells by 
electroporation. Cells grown in a 10cm plate at around 50% ~ 60% confluence were trypsinized 
and the pellet was collected in a 15 ml conical tube by centrifugation at 1,000 rpm for 5 minutes 
at 4˚C. One milliliter of OptiMEM was added into the tube to resuspend the pellet. The 
resuspended cells were mixed with 40 µg of plasmid DNA and transferred into a 0.4 cm cuvette. 
(Bio-Rad, Hercules, CA) The electroporation was performed with a voltage 220 V and 950 µF of 
capacitance.  
After electroporation, cells were transferred to a new cell culture plate with 11 ml fresh 
medium. Medium was changed after 24 hours to get rid of the dead cells and debris. Both the 
STAT3 constitutively active mutant with Flag-tag and the STAT3 dominant negative mutant 
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with HA-tag were selected by hygromycin resistance. 100 µg/ml of hygromycin was added into 
the medium, and multiple monoclones were picked up after at least one weeks culturing.   
The expression of both STAT3 constitutively active and STAT3 dominant negative mutants 
were controlled by 2 µg/ml of dexamethasone. Expression was determined by immunoblotting 
for STAT3 and the tags after 24 hr exposure to dexamethasone. Expressing clones were tested. 
 
 
2.6 RNA INTERFERENCE 
RNA interference (RNAi) is a process in which double-stranded RNA triggers the 
degradation of a homologous mRNA [247]. RNA interference is a technique that introduces 
exogenous, double-stranded RNAs (dsRNAs) which are complimentary to known mRNA's into a 
cell to specifically destroy that particular mRNA, thereby diminishing or abolishing gene 
expression and translation. I use the siRNAs specifically against human and mouse STAT3 to 
block the expression of the STAT3 gene in the target cell lines, which as a double confirmation 
of STAT3 antisense oligonucleotides. The siRNAs of human and mouse STAT3 and control 
siRNA were designed and ordered from the website of IDT. (http://www.idtdna.com) The 
sequence for human STAT3 siRNA is 5’-AUCCUGAAGG UGCUGCUCCTT-3’; the sequence 
for mouse STAT3 siRNA is 5’-UGCAUUCUCCUU GGCUCUUGAGGGUU-3’ and the 
sequence for control eGFP siRNA is 5’-GACCCGCG CCGAGGUGAAGTT-3’. Cells for RNA 
interference experiment were grown in an antibiotic-free medium before transfection. For a 
6-well plate, 4 μl of siRNA (20 μM) was incubated with 100 μl OptiMEM (GIBCO) per well 
(2ml medium) for 5 minutes, at the same time mix 4 μl of Lipofectamine 2000 (Invitrogen) with 
100μl OptiMEM, then mix the siRNA and Lipofectamine dilution and incubate at room 
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temperature for 20 minutes before adding into the culturing cells. Incubate the cells at 37˚C for at 
least 4 hours, change fresh antibiotic-free medium and let the cells recover for another 12 to 24 
hours [246].  
 
2.7 NUCLEAR EXTRACT PREPARATION AND EMSA  
Electrophoretic mobility shift assay (EMSA) is used for studying the binding between 
protein and specific DNA sequences. It can separate different types of complexes, such as 
monomer and dimer. These complexes can be recognized by transcription factor-specific 
antibodies that retard their mobility in gels for further identification. 
For STAT3 analysis by EMSA [248], confluent cells were harvested and washed with ice 
cold 1X PBS, with the pellets resuspended in 5-fold buffer A (10 mM HEPES, pH 7.9; 1.5 mM 
MgCl2; 10 mM KCl; 1 mM NaF; 0.5 mM DTT; 0.2 mM PMSF; 1 µg/µl profilin; 5 µg/µl 
aprotinin; 2 µg/µl leupeptin). After incubating on ice for 15 minutes, the nuclei were centrifuged 
at 4℃ for 10 seconds to obtain the nuclear-localized active transcription factors. Pellets were 
resuspended in 5-fold volumes (20μl ~ 100μl) cold buffer C (20 mM HEPES, pH 7.9; 1.5 mM 
MgCl2; 420 mM NaCl; 10 mM NaF; 1 mM Na3VO4; 25% glycerol; 0.2 mM EDTA; 0.5 mM 
DTT; 0.2 mM PMSF; 1 µg/µl profilin; 5 µg/µl aprotinin; 2 µg/µl leupeptin), incubated on ice for 
30 minutes and microcentrifuged for 2 minutes at the maximum speed. Aliquots were stored at 
-80℃. For EMSA, 10 µg of total extractions were used for each experimental point. EMSA was 
performed using a γ-32P labeled double strand oligonucleotide probe m67 (sense: 5’-GAT TTC 
CCG TAA ATC AT-3’) that binds STAT3 and STAT1 proteins [249]. Protein-DNA complexes 
were resolved by non-denaturing PAGE gel and detected by autoradiography. Anti-STAT3 
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antibodies (Upstate Biotechnology, Waltham, MA) were used for super shift assay and a 50-fold 
excess of unlabeled m67 probe was used in cold competition assay. 
 
2.8 IMMUNOBLOT  
Protein expression was determined by immunoblotting. Confluent cells were washed with 
ice cold 1 X PBS twice followed by treated with lyses buffer (100mM Tris-HCl, pH 6.8; 4% 
SDS; 20% glycerol and 5% B-mercapto-ethanol). Sample proteins were denatured at 100℃ for 5 
minutes in water bath before loading to the gel. After electrophoresis, the proteins were 
transferred to an Immobilon-P membrane. Membranes were blocked by 1% BSA. After blocking, 
membranes were incubated with a primary antibody: mouse anti STAT3 (Zymed); mouse anti 
GAPDH (abCam); mouse anti Flag (Stratagene); rabbit anti phosphor STAT3 (Cell Signaling) 
and rabbit anti HA-tag (Cell Signaling) at 4℃ for over night or at room temperature for 1 hour. 
The membranes were washed twice with 0.5 % Tween-20 (TBST) before incubated with 
secondary antibodies (Goat anti-mouse Ig or Goat anti-rabbit Ig, Biosource) [250].   
 
2.9 WOUND HEALING ASSAY 
Wound healing assay was used in vitro to assess cell motility in two dimensions. I used 
this assay to study the migration of both fibroblasts and human prostate tumor cells under the 
treatment of EGF and/or STAT3 inhibitors. Cells were plated on a 12-well plate and grown to 
confluence in their regular medium. Confluent cells were quiesced in 1% dialyzed FBS for 24 
hours before each experiment. A rubber policeman was used to create a denuded area. Cells were 
washed twice with PBS and treated with or without specific effectors for 24 hours. Photographs 
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were taken at hour 0 and hour 24, and the distance traveled was determined by subtracting the 
values obtained at hour 0 from hour 24. Mitomycin C (0.5 µg/ml) was added to the medium to 
prevent the confounding issue of cell proliferation [251]. 
  
2.10 INVASION ASSAY 
Invasive potential was determined in vitro by transmigration of an ECM [252]. Matrigel 
invasion chamber plates were purchased from Becton Dickinson/Biocoat (Bedford, MA). The 
Matrigel was used to mimic the environmental extracellular matrix. The upper surface of the 
matrix was challenged with 1.5 X 104 cells, a number derived from empirical experimentation. 
Cells were kept in serum-free medium containing 1% BSA for the first 24 h and then replaced 
with only serum-free medium for the remaining 24 h; the lower chamber contained medium 
containing 10% serum for the entire assay. Enumeration of the cells that invaded through the 
matrix over a 48-h period was accomplished by visually counting cells on the bottom of the filter, 
as per routine procedures, after any un-invaded cells were removed from the top of the filter with 
a cotton swab. In all of the cases, individual experiments were performed in duplicate chambers.  
 
2.11 ANNEXIN V STAINING FOR APOPTOSIS ASSAY 
The Annexin V staining is based on the observation that soon after apoptosis initiation, 
the membrane phosphatidyl-serine was translocated from the inner face of the plasma membrane 
to be exposed on the cell surface. Once on the cell surface, the phosphatidyl-serine can easily be 
detected by staining with a fluorescent conjugate of Annexin V, which is a protein that has high 
affinity for it. Annexin V-Cy3 kit (BioVision) was used in the apoptosis assay. Cells were 
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washed with 1 X PBS and then digested by Tripsin-EDTA. The pellets of cells were washed 
again by 1 X PBS twice and re-suspended in 500µl of 1 X Binding Buffer come with the kit. 
After incubation at room temperature for 5 minutes, Annexin V was added into the cells at a ratio 
of 1:100. The mixture was incubated in darkness for 10 minutes at room temperature and ready 
for counting fraction of Annexin V-staining cells under a fluorescence microscope [253]. 
 
2.12 PROLIFERATION ASSAY 
To study the viability and the toxicity of STAT3 inhibitors to the cell, the cells proliferation 
assay was performed by direct cell enumeration. A Z-series Coulter Counter (Coulter Corp) was 
used for the counting. Cells were counted by the Coulter Counter before being passed into new 
culture plates, after the treatment and growth for 48 or 72 hours to allow for one or two rounds of 
replication, cells were digested by Tripsin-EDTA (GIBCO) and then re-suspended in the original 
medium. The cells were diluted for 100 times in Isoton Ⅱsolution (Beckman) before counting 
[250]. 
 
2.13 STATISTICAL ANALYSES 
All data from migration, proliferation, invasion and apoptosis staining were analyzed and 
expressed as mean ± S.E.M. Evaluation of statistical significance was performed by use of T-test. 
A value of P < 0.05 was considered significant. 
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3.0  STAT3 IS REQUIRED BUT NOT SUFFICIENT FOR EGFR MEDIATED 
MIGRATION AND INVASION OF FIBROBLAST AND HUMAN PROSTATE 
CARCINOMA CELLS 
 
3.1 STAT3 ANTISENSE DECREASES EXPRESSION OF STAT3 IN NR6WT CELLS 
EGFR signaling activates STAT proteins in fibroblasts [187] and a variety of carcinoma 
cells [254] [255]. As our lab has previously shown, the prostate carcinoma cells present autocrine 
EGFR signaling. I determined whether this also invoked STAT3 activation. To study this issue, I 
used the motility model system, murine NR6WT fibroblasts, to examine EGF-triggered events as 
autocrine signaling is absent in these cells in contrast to prostate carcinoma cells which present 
autocrine EGFR-activating signaling loops [92], and thus the role of EGFR signaling can be 
cleanly parsed. The two human prostate cancer cell lines, DU145WT and PC3, present autocrine 
activation of endogenous and exogenous EGFR, as is the norm for prostate carcinoma cells. 
However, to study the function of EGFR signaling in these cells, I tested our prostate cells under 
conditions that minimize autocrine activation [187].  
Initially to parse STAT3 mediated responses from EGFR even in the fibroblasts, I 
downregulated the protein expression by using antisense oligonucleotides. This intervention 
reduced whole cell levels of STAT3 significantly in NR6WT fibroblasts (Fig 3-1). 
 
 
 
 
 50 
  
     NoTx    EGF  EGF/STAT3AS   EGF/Ctrl 
Figure 3-1. EGF increase the expression of STAT3 in NR6WT cells and it can be inhibited 
by STAT3 antisense.  
In murine fibroblasts, NR6WT cells, EGF exposure increased the expression of STAT3 at 
protein level, and this increase was inhibited by STAT3 antisense. Cells were quiesced in 0.5% 
FBS medium for 24 hours before the treatment. After quiescing, the NR6WT cells were treated 
with 1 nM EGF and/or 10 μM of oligonucleotides (STAT3 antisense or non-specific control) for 
over night. NoTx: non-treatment control; EGF: 1 nM human EGF; EGF/STAT3AS: 1 nM human 
EGF plus 10 μM mouse STAT3 antisense oligonucleotides; EGF/Ctrl: 1 nM human EGF plus 10 
μM non-specific oligonucleotides. The treated cells were lysised in 2X loading buffer and 
denatured at 100℃ in water bath for 5 minutes. Lysates were loaded to 10% acrylamide gel, 
transferred to an Immobilon-P membrane and immunoblotted with antibody against mouse 
STAT3. After being exposed, the membrane was stripped and immunoblotted with antibody 
against GAPDH as a loading control. 
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3.2 STAT3 ANTISENSE DECREASES DNA BINDING ACTIVITY OF STAT3 IN 
NR6WT CELLS 
The signaling pathway of STAT3 is a complicated process, cytoplasm STAT3 must be 
dimerized to get activated, and the performing of its transcriptional regulation function need the 
binding of STAT3 to its target DNA sequence. I used the EMSA assay to check the activity of 
STAT3 after STAT3 antisense treatment. A valuable aspect of EMSA is that is can separate 
different types of complexes, such as monomer and dimer, and it is easier to see the bound 
complex. In murine NR6WT fibroblasts cells, EGF exposure increased EMSA detection of the 
STAT3 band, which was negated upon addition of an antibody to mouse STAT3 (Fig 3-2). A 
competing binding of 50X concentration of cold nucleotide probe completely eliminated the 
band, showing the specificity of the binding of probe DNA and STAT3. 
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 Figure 3-2. Electrophoretic mobility shift assay (EMSA) detects EGF-dependent STAT3 
activity in NR6WT fibroblasts cells. 
EMSA analysis of STAT3 DNA-binding activity in nuclear extracts prepared from 
NR6WT mouse fibroblast cells using the γ-P32 labeled m67 probe. Negation of STAT3 shifting 
with the STAT3 antibody (STAT3Ab) shows the specificity of the STAT3 protein and cold 
competition (50X cold) demonstrates the specificity of the m67 probe. Cells were treated with 
1nM EGF, 1nM EGF plus 10uM STAT3 antisense (STAT3AS) or 10uM STAT3 antisense alone 
(cells were treated over night, which is 14-18hrs). Lower concentrations of cold competition 
assays (10X and 5X) were also performed and showed the similar trending results (data not 
shown).    
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3.3 STAT3 ANTISENSE DECREASES EXPRESSION OF STAT3 IN DU145WT CELLS 
Now that I could downregulate STAT3 activity in the NR6WT model cell, I changed my 
focus to the human prostate tumor cells, DU145WT cell. The DU145WT cells have a 
TGF-α/EGFR autocrine loop, which implies its independence or insensitivity of extraneous EGF 
stimulation. To overcome that disadvantage, a significant higher concentration of EGF and 
shorter treatment were applied on the DU145WT cells. The result showed that the STAT3 
antisense oligonucleotide reduced STAT3 levels in the DU145WT cells while no significant 
inhibition happened in the non-specific oligonucleotides control (Fig 3-3). 
 
Figure 3-3. EGF increase the expression of STAT3 in DU145WT cells and it can be 
inhibited by STAT3 antisense. 
DU145WT cells were quiesced in 0.5% FBS medium for 24 hours before the treatment. 
After quiescing, the DU145WT cells were treated with 10 μM of oligonucleotides (STAT3 
antisense or non-specific control – S3AS or CtrlAS, respectively) for over night followed by 
and/or 10 nM EGF for 15 minutes. NoTx: non-treatment control; EGF: 10 nM human EGF; 
EGF/STAT3AS: 10 nM human EGF plus 10 μM human STAT3 antisense oligonucleotides; 
EGF/Ctrl: 10 nM human EGF plus 10 μM non-specific oligonucleotides. The treated cells were 
lysised in 2 X loading buffer and denatured at 100oC in water bath for 5 minutes. Lysates were 
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loaded to 10% acrylamide gel, transferred to an Immobilon-P membrane and immunoblotted 
with antibody against mouse STAT3. After being exposed, the membrane was stripped and 
immunoblotted with antibody against GAPDH as a loading control. 
 
3.4 STAT3 ANTISENSE DECREASES DNA BINDING ACTIVITY OF STAT3 IN 
DU145WT CELLS 
To check the activity of STAT3 after STAT3 antisense treatment, we performed the 
EMSA assay. In human prostate tumor cell, DU145WT cells, EGF exposure increased EMSA 
detection of the STAT3 band, which was up-shifted upon addition of an antibody to murine 
STAT3 (Fig 3-4). A competing binding of 50X concentration of cold nucleotide probe 
eliminated the band, showing the specificity of the binding of probe DNA and STAT3. 
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  Figure 3-4. Electrophoretic mobility shift assay (EMSA) detects EGF-dependent STAT3 
activity in DU145WT human prostate tumor cells.  
EMSA analysis of STAT3 DNA-binding activity in nuclear extracts prepared from 
DU145WT human prostate tumor cells using the γ-P32 labeled m67 probe. Supershift with the 
STAT3 antibody (STAT3ab) shows the specificity of the STAT3 protein and cold competition 
(50X cold) demonstrates the specificity of the m67 probe. Cells were treated with 10nM EGF, 
10nM EGF plus 10uM STAT3 antisense or 10uM STAT3 antisense alone (STAT3AS) (cells were 
treated 14-18hr). Lower concentrations of cold competition assays (10X and 5X) were also 
performed and showed the similar trending results (data not shown). 
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3.5 STAT3 SIRNA DECREASES EXPRESSION OF STAT3 IN DU145WT CELLS 
Thought the antisense interventions worked, I sought a second, confirmatory way to 
downregulate STAT3 signaling. RNA interference (RNAi) is a process in which double-stranded 
RNA triggers the degradation of a homologous mRNA [Bass, 2003]. Today, RNA interference is 
a technique that introduces exogenous, double-stranded RNAs (dsRNAs) which are 
complimentary to known mRNA's into a cell to specifically destroy that particular mRNA, 
thereby diminishing or abolishing gene expression and translation., I used RNA interference to 
further confirm the blocking effect got from STAT3 antisense nucleotide. I downregulated the 
protein using siRNA directed against STAT3 in DU145WT cells (Fig 3-5). 
 
      NoTx    EGF    Si   EGF/Si   Ctrl    EGF/Ctrl 
Figure 3-5. EGF-mediated increase of STAT3 expression and activity is suppressed by 
STAT3 siRNA in DU145WT cells. 
EGF-mediated increase of STAT3 expression and activity is suppressed by STAT3 siRNA 
(S3Si) in DU145WT cells, but not by a non-target siRNA (against eGFP)(CtrlSi). DU145WT 
cells were grown in an antibiotic-free medium before being transfected by siRNA (20 μM) with 
Lipofectamine 2000 to a final concentration of 100 pM. After been transfected and recovered, 
DU145WT cells were quiesced in 0.5% FBS medium for 24 hours before the treatment. After 
quiescing, the DU145WT cells were treated with 10 nM EGF for 15 minutes. NoTx: 
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non-treatment control; EGF: 10 nM human EGF; Si: 100 pM of STAT3 siRNA transfection; ESi: 
10 nM human EGF plus 100 pM of human STAT3 siRNA; Ctrl: 100 pM of eGFP siRNA as 
non-specific control; EGF/Ctrl: 10 nM human EGF plus 00 pM of eGFP siRNA. The treated 
cells were lysised in 2 X loading buffer and denatured at 100℃ in water bath for 5 minutes. 
Lysates were loaded to 10% acrylamide gel, transferred to an Immobilon-P membrane and 
immunoblotted with antibody against human STAT3. After being exposed, the membrane was 
stripped and immunoblotted with antibody against GAPDH as a loading control. 
 
3.6 STAT3 SIRNA DECREASES EXPRESSION OF STAT3 IN PC3 CELLS 
To inhibit the STAT3 protein expression in a second human prostate cell line, PC3, I 
also used RNA interference. As with DU145WT cells, PC3 is a metastasis human prostate tumor 
cell, the difference between them is that PC3 is separated from bone metastases [237], not from 
brain as DU145 cells [238]. I also downregulated the STAT3 protein using siRNA directed 
against STAT3 mRNA sequence in PC3 cells (Fig 3-6). 
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 NoTx     EGF         Si    EGF/Si  Ctrl      EGF/Ctrl 
Figure 3-6. EGF-mediated increase of STAT3 expression and activity is suppressed by 
STAT3 siRNA in PC3 cells.  
EGF-mediated increase of STAT3 expression and activity is suppressed by STAT3 siRNA 
(S3Si) in PC3 cells, but not by a nontarget siRNA (against eGFP)(CtrlSi). PC3 cells were grown 
in an antibiotic-free medium before being transfected by siRNA (20 μM) with Lipofectamine 
2000 to a final concentration of 100 pM. After been transfected and recovered, PC3 cells were 
quiesced in 0.5% FBS medium for 24 hours before the treatment. After quiescing, the PC3 cells 
were treated with 10 nM EGF for 15 minutes. NoTx: non-treatment control; EGF: 10 nM human 
EGF; S3Si: 100 pM of STAT3 siRNA transfection; ES3Si: 10 nM human EGF plus 100 pM of 
human STAT3 siRNA; CtrlSi: 100 pM of eGFP siRNA as non-specific control; EGF/CtrlSi: 10 
nM human EGF plus 100 pM of eGFP siRNA. The treated cells were lysised in 2 X loading 
buffer and denatured at 100oC in water bath for 5 minutes. Lysates were loaded to 10% 
acrylamide gel, transferred to an Immobilon-P membrane and immunoblotted with antibody 
against human STAT3. After being exposed, the membrane was stripped and immunoblotted with 
antibody against GAPDH as a loading control. 
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3.7 STAT3 SIRNA DECREASES DNA BINDING ACTIVITY OF STAT3 IN DU145WT 
CELLS 
Inhibition of STAT3 protein expression of STAT3 siRNA was demonstrated by 
immunoblotting. Now the next question is whether the DNA-binding activity of STAT3 protein 
is also been suppressed by STAT3 siRNA. To get the answer, I also performed EMSA assay on 
STAT3 siRNA transfected DU145WT cells. The result is as same as in the previous STAT3 
antisense experiments. EGF significantly increases STAT3 binding activity while it can be 
reversed by STAT3 siRNA (Fig 3-7). 
   
NoTx       EGF      Si       EGF/Si   Ctrl     EGF/Ctrl 
STAT3 
Figure 3-7. The STAT3 siRNA negated EGF induced STAT3 activity in DU145WT prostate 
tumor cells. 
EMSA analysis of STAT3 DNA-binding activity in nuclear extracts prepared from DU145WT 
human prostate tumor cells using the γ-P32 labeled m67 probe. Cells were treated with 10nM 
EGF, 10nM EGF plus 100 pM STAT3 siRNA or 100 pM STAT3 antisense alone. A non-specific 
siRNA (eGFP siRNA) was used as control. NoTx: non-treatment control; EGF: 10 nM human 
EGF; S3Si: 100 pM of STAT3 siRNA transfection; ES3Si: 10 nM human EGF plus 100 pM of 
human STAT3 siRNA; CtrlSi: 100 pM of eGFP siRNA as non-specific control; EGF/CtrlSi: 10 
nM human EGF plus 100 pM of eGFP siRNA.  
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3.8 STAT3 ANTISENSE INHIBITS EGF INDUCED MIGRATION IN NR6WT CELLS 
Now that I could reproducibly limit STAT3 functioning, I asked what this did to 
EGFR-mediated cell migration. EGFR signaling drives motility in fibroblasts and carcinoma 
cells [256] and invasion of human prostate carcinoma cells [187] [257]. As such, we asked 
whether STAT3 might be critical for sustained motility and invasion in response to EGFR 
signaling. To quantitate cell motility, an in vitro wound healing assay was performed and 
demonstrated that the addition of STAT3 antisense oligonucleotides and the EGFR signaling 
pathway inhibitor PD153035 greatly decreased the migration distance of NR6WT fibroblast cell. 
The extent of migration inhibition was similar to that achieved by blocking EGFR kinase activity 
with the selective agent PD153035. Interestingly, the level of migration achieved with STAT3 
down regulation, and with PD153035 was below that of basal motility, strongly suggesting that 
either EGFR autocrine signaling via STAT3 or basal STAT3 was contributing to this cell 
behavior, as has been suggested earlier for EGFR autocrine activation [187]. 
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        NoTx     EGF     S3AS    E/S3AS   E/CtrlAS  E/PD153035 
Figure 3-8. STAT3 is required for EGF receptor mediated cell migration in NR6WT 
fibroblast cells. 
The migration distance of NR6WT fibroblast cells after treated with 1nM EGF for 24hr 
was significantly greater and this increase was suppressed by 10 μM STAT3 antisense (E/S3AS) 
but not scrambled non-specific oligonucleotides (CtrlAS). Additionally, EGF-induced motility 
was determined in the presence of the EGFR ATP binding inhibitor PD153035. * P < 0.01 
compared to EGF treatment. The migration distance (on the Y axis) is normalized to diluent 
alone (NoTx) within each experiment. For each experiment, no treatment was normalized as 
1-fold. Shown is mean ± s.e.m. for at least 3 experiments each performed in triplicate and 
normalized to no treatment. NoTx: non-treatment; EGF: 1 nM human EGF; S3AS: 10 μM mouse 
STAT3 antisense oligonucleotides; E/S3: 1 nM human EGF plus 10 μM mouse STAT3 antisense 
oligonucleotides; E/Ctrl: 1 nM human EGF plus 10 μM non-specific oligonucleotides; 
E/PD153035: 1 nM human EGF with 500 nM PD153035. All the cells were grown in a medium 
with 0.5 µg/ml Mitomycin C to inhibit proliferation. 
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3.9 STAT3 ANTISENSE INHIBITS EGF INDUCED MIGRATION IN DU145WT CELLS 
Based on the inhbition of motility noted in the fibroblasts, I proceeded to ask whether 
STAT3 might be critical for sustained motility and invasion in response to EGFR signaling in the 
prostate carcinoma cells. STAT3 downregulation greatly decreased the migration distance of 
DU145WT prostate cancer cell as well as in NR6WT fibroblast cell. The results showed that the 
migration distance of DU145WT cells after treated with 10 nM EGF for 24hr was significantly 
greater and this increase was suppressed by 10 μM STAT3 antisense (S3AS) but not scrambled 
non-specific oligonucleotides (Ctrl). Additionally, EGF-induced motility was determined in the 
presence of the EGFR inhibitor PD153035 (Fig 3-9). 
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     NoTx      EGF    S3AS       E/S3AS    E/CtrlAS   E/PD153035 
Figure 3-9. STAT3 is required for EGF receptor mediated cell migration in human 
prostate tumor cells. 
The results showed that the migration distance of DU145WT cells after treated with 10 nM 
EGF for 24hr was significantly greater and this increase was suppressed by 10 μM STAT3 
antisense (S3AS) but not scrambled non-specific oligonucleotides (Ctrl). Additionally, 
EGF-induced motility was determined in the presence of the EGFR inhibitor PD153035.* P < 
0.01 compared to EGF treatment. The migration distance (on the Y axis) is normalized to diluent 
alone (NoTx) within each experiment. Shown is mean ± s.e.m. for at least 3 experiments each 
performed in triplicate and normalized to no treatment. NoTx: non-treatment; EGF: 1 nM 
human EGF; S3AS: 10 μM mouse STAT3 antisense oligonucleotides; E/S3: 1 nM human EGF 
plus 10 μM mouse STAT3 antisense oligonucleotides; E/Ctrl: 1 nM human EGF plus 10 μM 
non-specific oligonucleotides; E/PD153035: 1 nM human EGF with 500 nM PD153035. All the 
cells were grown in a medium with 0.5 μg/ml Mitomycin C to inhibit proliferation. 
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3.10 STAT3 SIRNA INHIBITS EGF INDUCED MIGRATION IN DU145WT AND 
PC3 HUMAN PROSTATE TUMOR CELLS 
Since the STAT3 siRNA inhibit STAT3 expression and its DNA binding activity as well 
as STAT3 antisense oligonucleotides, it is reasonable to posit that STAT3 siRNA also inhibits 
the EGF induced motility as the later. This would further confirm the specificity of the antisense 
approach to that of disruption of STAT3 function. To study cell motility, an in vitro wound 
healing assay was performed and demonstrated that the addition of human STAT3 siRNA 
greatly decreased the migration distance of DU145WT prostate cancer cell (Fig 3-10). 
The same experiment was performed in another aggressive, androgen-independent human 
prostate tumor cell line, the PC3 cells. This was done to show that the results were not unique to 
a single cell line. To study cell motility, an in vitro wound healing assay was performed and 
demonstrated that the addition of human STAT3 siRNA greatly decreased the migration distance 
of PC3 prostate cancer cell (Fig 3-10). 
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NoTx    EGF       S3Si      E/S3Si   CtrlSi     E/CtrlSi 
Figure 3-10. STAT3 is required for EGF receptor mediated cell migration in human 
prostate tumor cells. 
The migration distance of DU145WT (A) and PC3 (B) prostate tumor cells after 
treatment with 10 nM EGF for 24hr was significantly greater and these increases were 
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suppressed by STAT3 siRNA (S3Si) but not siRNA against eGFP (CtrlSi). Shown is mean ± s.e.m. 
for at least 3 experiments each performed in triplicate. * P < 0.01 compared to EGF treatment. 
The migration distance (on the Y axis) is normalized to diluent alone (NoTx) within each 
experiment. NoTx: non-treatment control; EGF: 10 nM human EGF; Si: 100 pM of STAT3 
siRNA transfection; ESi: 10 nM human EGF plus 100 pM of human STAT3 siRNA; Ctrl: 100 pM 
of eGFP siRNA as non-specific control; EGF/Ctrl: 10 nM human EGF plus 100 pM of eGFP 
siRNA. All the cells were grown in a medium with 0.5 μg/ml Mitomycin C to inhibit proliferation. 
 
 
3.11 STAT3 ANTISENSE INHIBITS EGF INDUCED INVASION IN DU145WT 
As motility is a key component to tumor cell invasion [1], we determined whether this 
inhibition affected tumor cell invasion by examining the transmigration of a Matrigel barrier. 
Antisense oligonucleotides directed against STAT3 limited DU145WT tumor cell transmigration 
to below the levels noted in the absence of added EGF.  
This extent of inhibition is expected as both DU145WT and PC3 cells express EGFR 
ligands [258], which generate autocrine stimulatory signals in the physical confines of a matrix, 
and Matrigel contains competent levels of EGFR ligands [259]. That this is due to EGFR 
signaling is shown by blockade using the selective inhibitor PD153035. This inhibitor reduced 
not only EGF-enhanced invasiveness but also the invasiveness in the absence of exogenous EGF. 
Thus, during transmigration of Matrigel the cells are in an active EGFR signaling mode. The 
results showed that STAT3 antisense (S3AS) treated DU145WT cells have a much lower 
invasion rate than those cells treated by EGF (Figure 3-11). 
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 Figure 3-11. STAT3 is critical for EGFR mediated prostate tumor cell invasiveness 
STAT3 antisense (S3AS) treated DU145WT cells have a much lower invasion rate than 
those cells treated by EGF while non-specific control oligonucleotides had no effect on the 
invasion. Shown is mean ± s.e.m. for at least 3 experiments each performed in triplicate. * P < 
0.05 compared to EGF treatment. The invasiveness as determined by cell number transmigrated 
through the Matrigel (on the Y axis) is normalized to diluent alone (NoTx) within each 
experiment. NoTx: non-treatment; EGF: 10 nM human EGF; S3AS: 10 μM human STAT3 
antisense oligonucleotides; E/S3: 10 nM human EGF plus 10 μM human STAT3 antisense 
oligonucleotides; CtrlAS: 10 μM non-specific oligonucleotides; E/Ctrl: 10 nM human EGF plus 
10 μM non-specific oligonucleotides.  
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3.12 STAT3 SIRNA INHIBITS EGF INDUCED INVASION IN DU145WT AND PC3 
HUMAN PROSTATE CANCER CELLS 
Since the STAT3 siRNA inhibit EGFR mediated migration as well as STAT3 antisense 
oligonucleotides, it is reasonable to posit that STAT3 siRNA also inhibits the EGFR induced 
invasion as the later. To study the invasion of human prostate cancer cells, examining the 
transmigration of a Matrigel barrier was performed. The results showed that STAT3 antisense 
(S3AS) treated DU145WT and PC3 cells have a much lower invasion rate than those cells 
treated by EGF (Figure 3-12). 
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NoTx     EGF      S3Si     E/S3Si      CtrlSi      E/CtrlSi 
Figure 3-12. STAT3 is critical for EGFR mediated prostate tumor cell invasiveness. 
STAT3 siRNA (S3Si) inhibited EGFR mediated invasion of DU145WT (A) and PC3 (B) 
prostate tumor cells, whereas eGFP-directed siRNA (CtrlSi) did not. Shown is mean ± s.e.m. for 
at least 3 experiments each performed in triplicate. * P < 0.01 compared to EGF treatment. The 
invasiveness as determined by cell number transmigrated through the Matrigel (on the Y axis) is 
normalized to diluent alone (NoTx) within each experiment. NoTx: non-treatment control; EGF: 
10 nM human EGF; Si: 100 pM of STAT3 siRNA transfection; E/Si: 10 nM human EGF plus 100 
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pM of human STAT3 siRNA; Ctrl: 100 pM of eGFP siRNA as non-specific control; EGF/Ctrl: 10 
nM human EGF plus 100 pM of eGFP siRNA. 
 
3.13 STAT3 IS NOT SUFFICIENT FOR MIGRATION IN NR6WT CELLS 
The foregoing data demonstrate that STAT3 activity is required for increased cell 
migration and invasion upon EGFR signaling. Up regulation of STAT3 levels in various cancers 
[206] [254] [255] might even suggest this functions as an ‘oncogenes’ or ‘tumor progression’ 
gene. Thus, we asked whether upregulation was sufficient to drive these behaviors. A 
constitutively active (CA) STAT3 mutant failed [260] to drive motility of NR6WT cells in the 
absence EGF (Figure 3-13). A dominant negative (DN) STAT3 construct did block EGF-induced 
motility, as expected. The STAT3 constructs were induced by dexamethasone to avoid 
adaptation or cellular modifications during prolonged selection; the dexamethasone by itself had 
only a small negative effect on migration that was minimal compared to the effects of either EGF 
or the constructs. These data are consistent with STAT3 being required, but not sufficient, for 
transcriptional activation of either replacement proteins or modulation of the proteome at the 
transcriptional to enable a locomotive state. 
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Figure 3-13. STAT3 is not sufficient for EGFR-mediated migration in NR6WT 
fibroblasts. 
(A) Immunoblotting demonstrates expression of STAT3 dominant negative and 
constitutively active mutants in NR6WT cells upon transcriptional up regulation by 
dexamethasone. Cells were quiesced in 0.5% FBS medium for 24 hours before the treatment. 
After quiescing, the NR6WT cells were treated with 1 nM EGF and/or 2 μg/ml Dexamethasone  
for over night. The treated cells were lysised in 2X loading buffer and denatured at 100℃  in 
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water bath for 5 minutes. Lysates were loaded to 10% acrylamide gel, transferred to an 
Immobilon-P membrane and immunoblotted with antibody against phosphorylated STAT3 
(STAT3 Tyr705) and the special expression tag on the STAT3 mutants (For STAT3 dominant 
negative, HA-tag; for STAT3 constitutively active, Flag-M2). Shown are representative blots of 
at least three experiments each. NoTx: non-treatment; EGF: 1 nM human EGF; EGF/Dexa: 1 
nM human EGF with 2 μg/ml Dexamethasone; Dexa: 2 μg/ml Dexamethasone. After being 
exposed, the membrane was stripped and immunoblotted with antibody against GAPDH as a 
loading control. (B) The STAT3 constitutively active mutant did not drive motility of NR6WT 
cells in the absence or presence EGF, while the dominant-negative construct blocked both basal 
and EGF-induced motility, which indicates STAT3 is critical but not sufficient for the motility. 
Shown is mean ± s.e.m. for at least 3 experiments each performed in triplicate. * P < 0.01 
compared to EGF treatment. The migration distance (on the Y axis) is normalized to diluent 
alone of the empty vector (NoTx) within each experiment. NoTx: non-Treatment; EGF: 1 nM 
human EGF; EGF/Dexa: 1 nM human EGF with 2 μg/ml Dexamethasone; Dexa: 2 μg/ml 
Dexamethasone. 
 
 
3.14 STAT3 ANTISENSE DOES NOT INHIBIT EGFR MEDIATED 
PROLIFERATION IN NR6WT FIBROBLAST CELLS 
High expression of STAT3 is found correlated with tumor cells proliferation in many human 
cancers [261] [262] [263]. If STAT3 blockade or downregulation limited proliferation, this 
would confound longer term migration and invasion assessments. In the above, the time period 
 73 
and manipulations precluded proliferation from substantively contributing to migration and 
invasion, but in vivo, the situation would be reversed.  
I also expected a decrease of NR6WT proliferation after the treatment of STAT3 antisense 
oligonucleotides. Surprisingly, no significant change was found in the in vitro proliferation assay 
between NR6WT cells treated with EGF and EGF plus STAT3 antisense oligonucleotides (Fig 
3-14).  
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Figure 3-14. STAT3 antisense does not inhibit EGFR mediated proliferation in NR6WT 
cells. 
EGF plus STAT3 antisense treated NR6WT cells have no statistically significant change on 
proliferation with those cells treated by EGF alone. The cell proliferation (on the Y axis) is 
normalized to diluent alone (NoTx) within each experiment. NoTx: non-treatment control; EGF: 
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1 nM human EGF; EGF/STAT3AS: 1 nM human EGF plus 10 μM mouse STAT3 antisense 
oligonucleotides; STAT3AS: 10 μM mouse STAT3 antisense oligonucleotides. Shown is mean ± 
s.e.m. for at least 3 experiments each performed in triplicate. 
 
3.15 STAT3 ANTISENSE DOES NOT INHIBIT EGFR MEDIATED 
PROLIFERATION IN DU145WT CELLS 
Cancer cells present unique signaling pathways and dependencies. As such we examined the 
effect of STAT3 downregulation on the prostate carcinoma cells. It has been reported that many 
carcinoma cells undergo apoptosis or proliferation arrest in the face of STAT3 downregulation 
[246] [264] [265]. As such I expected a decrease of DU145WT proliferation after the treatment 
of STAT3 antisense oligonucleotides. Surprisingly, again, no significant change was found in the 
in vitro proliferation assay between DU145WT cells treated with EGF and EGF plus STAT3 
antisense oligonucleotides (Fig 3-17). Similar experiments were performed with STAT3 siRNA 
to block the STAT3 expression instead of STAT3 antisense and got the same results (Data not 
shown). 
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Figure 3-15. STAT3 antisense does not inhibit EGFR mediated proliferation in DU145WT 
cells. 
EGF plus STAT3 antisense treated DU145WT cells have no statistically significant 
change on proliferation with those cells treated by EGF alone. The cell proliferation (on the Y 
axis) is normalized to diluent alone (NoTx) within each experiment. NoTx: non-treatment control; 
EGF: 1 nM human EGF; EGF/STAT3AS: 1 nM human EGF plus 10 μM human STAT3 antisense 
oligonucleotides; STAT3AS: 10 μM human STAT3 antisense oligonucleotides. Shown is mean ± 
s.e.m. for at least 3 experiments each performed in triplicate. 
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4.0  STAT3 IS REQUIRED IN CASPASE 3 INDUCED HUMAN PROSTATE 
CARCIMONA CELL APOPTOSIS 
 
4.1 MICROARRAY DATA SHOWS SIGNIFICANT CHANGES OF SOME PROTEINS’ 
TRANSCRIPTION LEVELS AFTER EGF AND/OR STAT3 ANTISENSE TREATMENT 
IN NR6WT CELLS 
To further probe the role of the EGF/STAT3 pathway, an initial microarray analysis was 
performed on NR6WT cells, thus avoiding variable amounts of autocrine signalling, to determine 
transcripts that were altered by EGF in a STAT3-dependent manner. Interestingly, these did not 
include the constituents of the well known epigenetic cascades but rather extracellular matrix or 
cell cytoskeleton components. It is possible that the enzymatic epigenetic effects are regulated by 
the other EGFR-induced transcription cascades, and that STAT3 primarily functions to provide 
the motors and pathways for motility. Of note, we did not detect either collagenase-1 (MMP-1) 
or stromelysin-2 (MMP-10) that was seen to be up regulated in T24 bladder carcinoma cells 
[147]; this discrepancy is likely due to our examining the non-transformed NR6WT fibroblasts 
presenting a more limited set of transcription changes, though the two changes noted in the 
fibroblasts also were found in the cancer cells 
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EGF/NoT
x 
Expressio
n Ratio 
EGF + 
STAT3AS/NoT
X Expression 
Ratio 
Genbank 
Number Name 
   EGF up STAT3AS down 
1.514  0.823  3883001 myotubularin related protein 1 
1.518  1.027  3600099 ATP-dependent metalloprotease FtsH1 
1.605  0.918  348968 Procollagen, type XVIII, alpha 1  
1.608  1.086  4160555 kinesin-related mitotic motor protein 
1.782  1.255  2460054 acetylcholinesterase-associated collagen  
2.115  1.058  487140 disintegrin-related protein 
2.194  0.923  193565 Selectin, platelet 
2.392  1.290  1171097 Procollagen, type XVIII, alpha 1 
2.734  0.885  193559 endothelial ligand for L-selectin 
3.165  0.824  1568624 Laminin, alpha 4 
3.283  1.310  192663 alpha-1 type II collagen 
3.409  1.443  4159992 endomucin mRNA 
3.478  1.277  2465567 A disintegrin and metalloprotease domain (ADAM) 7 
3.820  1.052  3929109 Kinesin heavy chain member 5C 
4.992  1.189  4587237 T-cadherin 
5.201  0.908  2995448 Midline 1 
7.539  1.411  1666650 Cyritestin 1 
   EGF down STAT3AS up 
0.209  1.378  2160436 Procollagen, type XV 
0.236  1.231  1401050 Dishevelled 2, dsh homolog 
0.331  0.841  3219171 collagen a1(V) 
0.349  0.867  1617401 ena/VASP 
0.380  0.937  2104494 Dynactin 1 
0.413  0.754  220589 Lysyl oxidase 
0.442  0.989  1313903 collapsin-1 
0.474  0.796  595918 Capping protein alpha 2 
0.492  0.908  2282607 A disintegrin and metalloprotease domain 
0.523  1.093  396816 BM-90/fibulin extracellular matrix glyroprotein 
0.633  1.002  5771423 delta-sarcoglycan 
0.648  1.203  53991 T-complex protein 10a 
0.651  1.454  348971 Desmin 
0.664  1.453  537490 Integrin alpha V 
0.669  1.118  1742912 Rab 11 
0.670  0.982  497774 Fascin 1 
0.690  1.120  193223 Focal adhesion kinase 
 78 
Table 4 Microarray in NR6WT cells shows some proteins’ mRNA expression level 
changed significantly after EGF treatment and went back after blocking the STAT3 by antisense 
nucleotide.  
The NR6WT cells were quiesced in 0.5% FBS MEMα media for 24 hours before 
treatment with 1nM of EGF and/or 10µM of mouse STAT3 antisense nucleotide (5’-GTT CCA 
CTG AGC CAT CCT GC-3’) for another 24 hours. RNA from the treated cells was then purified. 
and prepared for microarray analysis. Affymetrix U74AV2 murine genome array chip was 
choosen for the microarray. 5 μg of purified total RNA were added into a 20 μl first strand 
reaction with 200 U of SuperScript II (Invitrogen) and 1 µg T7 primer in 1X first strand buffer 
(Invitrogen) followed by a 42°C incubation for 1 hour. Second strand synthesis was performed 
followed by purification according to the manufacturer’s protocol (Affymetrix). The purified 
cDNA was amplified to produce 70-120 μg of biotin labeled cRNA. 
Murine U74Av2 GeneChip probe arrays were pre-hybridized in 200μl of the 
hybridization cocktail (containing 10 µg of labeled cRNA) according to the manufacturer’s 
protocol. 15 μg of labeled cRNA were fragmentedand and resuspended.  
The raw data from microarray were normalized with the Affymetrix Microarray suite 5.0, 
based on the housekeeping gene expression profile. Expression values were adjusted to the 
intensity of the expression value of the 100 housekeeping genes. 
 
4.2 EGF INHIBITS THE EXPRESSION OF VASP IN NR6WT CELLS, WHICH CAN 
BE REVERSED BY STAT3 SIRNA 
Previous research demonstrated VASP as a negative regulator of fibroblast cell motility 
[168]. We also noticed significant decrease of VASP mRNA expression after EGF treatment in 
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NR6WT cells. I used immunoblot to examine if the protein level of VASP also changed. The 
results showed that 1 nM EGF suppressed VASP protein expression in NR6WT cells 30 minutes 
after treatment and continues for about 24 hours. (Data not shown) The inhibition of VASP 
expression was reversed by STAT3 siRNA, which implicated STAT3 may play a role in EGF 
mediated VASP expression (Fig 4-1). 
Caspase 3 is a well known protein that plays a central role in effecting apoptosis. We also 
found dramatically change of Caspase 3 mRNA after EGF and STAT3 antisense stimulation in 
microarray screening. Preliminary data shows decreased Caspase 3 protein expression after EGF 
stimulation. The inhibition of Caspase 3 expression was reversed by STAT3 siRNA, which 
implicated STAT3 may play a role in EGF mediated Caspase 3 expression and apoptosis 
inhibition (Fig 4-1). 
 Figure 4-1. EGF inhibits the expression of VASP and Caspase-3 in NR6WT cells, which can 
be reversed by STAT 3 siRNA. 
In murine fibroblasts, NR6WT cells, EGF exposure decreased the expression of VASP 
and Caspase-3 at protein level, and this decrease was reversed by STAT3 siRNA. The NR6WT 
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cells were transfected with 20 nM of STAT3 siRNA or non-specific control (eGFP siRNA) for at 
least 4 hours and recovered in fresh antibiotics-free medium for 24 hours. After that, cells were 
quiesced in 0.5% FBS medium for another 24 hours before the addition of EGF. NoTx: 
non-treatment control; EGF: 1 nM human EGF; EGF/STAT3si: 1 nM human EGF plus 20 nM 
mouse STAT3 siRNA; EGF/Ctrl: 1 nM human EGF plus 20 nM eGFP siRNA. The treated cells 
were lysised in 2X loading buffer and denatured at 100℃ in water bath for 5 minutes. Lysates 
were loaded to 10% acrylamide gel, transferred to an Immobilon-P membrane and 
immunoblotted with antibodies against mouse VASP and Caspase-3. After being exposed, the 
membrane was stripped and immunoblotted with antibody against GAPDH as a loading control.  
 
 
4.3 EGF INHIBITS THE EXPRESSION OF VASP AND CASPASE 3 IN DU145WT 
CELLS AND CAN BE REVERSED BY STAT3 SIRNA 
As mentioned above, VASP had been shown to be a negative regulator of fibroblast cell 
motility [168]. We also found significant decrease of VASP mRNA expression after EGF 
treatment in NR6WT cells and confirmed it by immunoblot. The inhibition of VASP and 
Caspase-3 expression by EGF and reversion by STAT3 siRNA also was observed in DU145 
human prostate tumor cells, which implicated STAT3 may plays a role in EGF mediated VASP 
and Caspase 3 expression and the tumor cell resistance to apoptosis (Fig 4-2). Similar results 
were observed in PC3 cells (data not shown). 
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 Figure 4-2. EGF inhibits the expression of VASP and Caspase-3 in DU145WT cells, 
which can be reversed by STAT 3 siRNA. 
In DU145WT human prostate cancer cells, EGF exposure decreased the expression of 
VASP and Caspase-3 at protein level, and this decrease was reversed by STAT3 siRNA. The 
DU145WT cells were transfected with 40 nM of STAT3 siRNA or non-specific control (eGFP 
siRNA) for at least 4 hours and recovered in fresh antibiotics-free medium for 24 hours. After 
that, cells were quiesced in 0.5% FBS medium for another 24 hours before the addition of EGF. 
NoTx: non-treatment control; EGF: 10 nM human EGF; EGF/STAT3si: 10 nM human EGF plus 
40 nM human STAT3 siRNA; EGF/Ctrl: 10 nM human EGF plus 40 nM eGFP siRNA. The 
treated cells were lysised in 2X loading buffer and denatured at 100℃ in water bath for 5 
minutes. Lysates were loaded to 10% acrylamide gel, transferred to an Immobilon-P membrane 
and immunoblotted with antibodies against VASP and Caspase-3. After being exposed, the 
membrane was stripped and immunoblotted with antibody against GAPDH as a loading control. 
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4.4 STAT3 IS REQUIRED FOR RESISTANCE TO TNF-Α INDUCED APOPTOSIS OF 
DU145WT CELLS 
Since Caspase 3 plays a critical role in apoptosis and we found some relationship 
between EGF, STAT3 and Caspase 3 expression, it is quite reasonable to querying if the first 2 
proteins also involved in Caspase 3 mediated apoptosis. Most recent research indicated that EGF 
protects prostate cancer cells from apoptosis [266], which put the role that EGFR mediated 
signalling pathway plays in apoptosis under focus. An Annexin-V staining assay for apoptosis 
induced by TNF-α was performed. Result shows EGF protect DU145WT human prostate tumor 
cells from apoptosis, and the protection can be reversed by STAT3 siRNA, which indicated a 
major role STAT3 maybe plays in Caspase 3 mediated apoptosis (Fig 4-4). I did not see major 
cell death in the experiment, but still sensitivity to the TNF-α. A similar apoptosis assay that 
induced by cisplatin instead of TNF-α was also performed and showed the same result. (Data not 
shown) 
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Figure 4-3. Annexin-V staining data for apoptosis in DU145WT prostate tumor cells with 
the treatment of EGF and STAT3 siRNA 
EGF protects apoptosis induced by TNF-α in DU145WT cells, while the inhibition of 
apoptosis can be reversed by STAT3 siRNA. The cells were transfected by human STAT3 siRNA 
and followed by a 6 hours treatment with 30 ng/ml TNF-α and/or 2 nM EGF. Shown is mean ± 
s.e.m. for at least 3 experiments each performed in triplicate. * P < 0.01 compared to EGF 
treatment. The migration distance (on the Y axis) is normalized to diluents alone of the NoTx 
within each experiment. NoTx: non-Treatment; EGF: 2 nM human EGF; STAT3si: 40 nM human 
STAT3 siRNA; EGF/STAT3si: 2 nM human EGF with 40 nM human STAT3 siRNA; eGFPsi:40 
nM eGFP control siRNA; EGF/eGFPSi: 2 nM human EGF with 40 nM control eGFP siRNA; 
TNF-α: 30 ng/ml human TNF-α.  
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4.5 STAT3 IS REQUIRED FOR RESISTANCE TO TNF-Α INDUCED APOPTOSIS IN 
PC3 CELLS 
The same Annexin-V staining assay for apoptosis is also performed in another human 
prostate cancer cell line, the PC3 cells. Result shows EGF protect PC3 human prostate tumor 
cells from TNF-α induced apoptosis, and the protection can be reversed by STAT3 siRNA, 
which is the same as what I got from DU145WT cells. (Fig 4-5) I did not see major cell death in 
the experiment, but still sensitivity to the TNF-α. A similar apoptosis assay, which induced by 
cisplatin instead of TNF-α, was also performed and showed the same result. (Data not shown) 
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Figure 4-4. Annexin-V staining data for apoptosis in PC3 prostate tumor cells with the 
treatment of EGF and STAT3 siRNA. 
The EGF induced suppression of apoptosis was turn over by STAT3 siRNA in PC3 human 
prostate tumor cells. The cells were transfected by human STAT3 siRNA and followed by a 6 
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hours treatment with 30 ng/ml TNF-α and/or 2 nM EGF. Shown is mean ± s.e.m. for at least 3 
experiments each performed in triplicate. * P < 0.01 compared to EGF treatment. The migration 
distance (on the Y axis) is normalized to diluents alone of the NoTx within each experiment. 
NoTx: non-Treatment; EGF: 2 nM human EGF; STAT3si: 40 nM human STAT3 siRNA; 
EGF/STAT3si: 2 nM human EGF with 40 nM human STAT3 siRNA; eGFPsi:40 nM eGFP 
control siRNA; EGF/eGFPsi: 2 nM human EGF with 40 nM control eGFP siRNA; TNF-α: 30 
ng/ml human TNF-α.  
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5.0  DISCUSSION CHAPTER 
Carcinogenesis is a multi-step process, in which cancer cells disseminate from a localized 
primary tumor mass to both invade local tissue and metastasize to distant organs. It has been well 
known that tumor invasiveness is a distinct character of tumor progression involving induced 
motility in addition to dysregulated proliferation. Since there is no catholicon for the current 
anti-cancer treatments, disrupting or at least inhibiting the tumor invasiveness would greatly 
ameliorate the morbidity and mortality. In this study, we investigated whether activated STAT3 
protein is involved in the EGF receptor mediated migration in fibroblasts and human prostate 
cancer cells and the invasiveness of the latter. EGF increased STAT3 activity along with cell 
motility and invasiveness of these cells. Decreased expression and activation of STAT3 by 
treatment with STAT3 antisense oligo nucleotides or siRNA or in the presence of a dominant 
negative mutant of STAT3 abrogated migration and invasion. The results together, indicated that 
STAT3 could be a targeted critical element in the EGF- mediated cell migration and invasion of 
prostate carcinoma cells. 
Epigenetic events, in addition to transcriptome changes signaled through STAT3, also 
contribute to tumor cell motility and invasion. Comparing the migration of NR6WT cells 
expressing constitutively activated STAT3 to those expressing the STAT3 dominant negative 
mutants, it is interesting to find that constitutively activated STAT3 alone does not increase cell 
motility, nor does it increase EGF-stimulated migration. This result suggests that STAT3 is not 
sufficient for cell migration but that it provides for end effectors that require additional signals 
for either activation or full phenotypic expression. EGF stimulation of a cell results in the 
activation of multiple pathways that lead to transcriptional control including Src, PLC-γ, PI3-K, 
Ras/MAPK and JAK/STAT [38]. These pathways are often functionally interlinked [267]. Thus, 
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the need for de novo transcription and translation that one notes during growth factor induced 
motility [268] [269], can be accomplished by a number of downstream transcription factors but 
requires STAT3 in addition to the previously determined PLCγ pathway [270]. Recently, it has 
been noted that EGFR signalling promotes progression of T24 bladder carcinoma cells via 
STAT3 upregulation of transcription, including that of matrix metaloproteinases [271]. 
To further probe the role of the EGF/STAT3 pathway, an initial microarray analysis was 
performed on NR6WT cells, thus avoiding variable amounts of autocrine signalling, to determine 
transcripts that were altered by EGF in a STAT3-dependent manner. (The subset of these 
transcripts that are classified as related motility and cell adhesion are provided in the 
Supplemental Table). Interestingly, these did not include the constituents of the well known 
epigenetic cascades but rather extracellular matrix or cell cytoskeleton components. It is possible 
that the enzymatic epigenetic effects are regulated by the other EGFR-induced transcription 
cascades, and that STAT3 primarily functions to provide the motors and pathways for motility. 
Of note, we did not detect either collagenase-1 (MMP-1) or stromelysin-2 (MMP-10) that was 
seen to be upregulated in T24 bladder carcinoma cells [271]; this discrepancy is likely due to our 
examining the non-transformed NR6WT fibroblasts presenting a more limited set of 
transcription changes, though the two changes noted in the fibroblasts also were found in the 
cancer cells. Obviously, these early hints are under active further investigation as these questions 
lie beyond the scope of the current communication.  
Recent studies suggest that aberrant STAT3 signalling may play an important role in the 
carcinogenesis of prostate cancer. Previous data from other groups shows higher 
phospho-STAT3 expression in prostate tumor tissues than in adjacent normal tissues [272] [273], 
and that this correlates with invasiveness [252]. We also found increased expression of STAT3 
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protein in prostate tumor tissues compared to normal tissue from the same patient (data not 
shown, as similar data have been previously published). It is quite reasonable that the high 
expressed pSTAT3 in prostate tumor tissues is from the increased expression of STAT3 as well 
as activation by autocrine growth factor signalling [274]. Our study indicating that STAT3 is 
critical for invasion of prostate cancer cells DU145WT and PC3, secondary to increased cell 
motility is consistent with these findings and provide for a mechanism by which phosphorulated 
STAT exerts its effects.  
Contrary to other studies [275] [276], we didn’t find decreased tumor cell numbers upon 
STAT3 down regulation; this may be due to the incomplete nature of such interventions (though 
the other studies suffered from similar non-quantitative abrogation), high levels of autocrine 
EGFR signalling overcoming this limitation via other pathways, or likely the shorter time course 
of our experiments. However, in accord with these other studies, when we overexpressed the 
dominant-negative STAT3 construct in DU145WT cells, we noted a high degree of apoptosis in 
these cells (for the experiments in Figure 19, we achieved a lower, non-apoptotic level of DN 
STAT3); our failure to established stable clones expressing this dominant-negative construct 
likely relates to this inhibition of proliferation and/or increased apoptosis. In addition, when we 
stress the cells using apoptosis inducers the blockade of STAT3 does increase tumor cell 
apoptosis. As such, we feel that this discrepancy is more likely a quantitative rather than a 
qualitative effect. 
VASP is known as a negative regulator of fibroblast motility [80]. The result from 
microarray indicated significant change of VASP mRNA after the treatment of EGF and STAT 3 
antisense (Table 4). Immunoblot on NR6WT fibroblast cells showed the expression of VASP 
protein is also inhibited by EGF. The inhibition can be observed 30 minutes after the EGF 
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treatment and last for about 24 hours. After adding STAT 3 antisense or STAT 3 siRNA, the 
expression of VASP goes back to normal level. This result supports the previous finding, as EGF 
suppressed VASP expression, it is quite reasonable to understand that EGF induced fibroblast 
cell motility can be turned over by blocking the expression of STAT 3, which is needed for 
VASP expression. Further experiments also showed that EGF can suppress VASP expression in 
DU145WT and PC3 human prostate tumor cells, though not as significant as in NR6WT 
fibroblast cells. The reason could be high autocrine level of EGF in those cancer cells. 
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6.0  CONCLUSIONS AND SPECULATION 
6.1 CONCLUSIONS 
Growth factor-induced migration is a rate-limiting step in tumor invasiveness. The 
molecules that regulate this cellular behavior would represent novel targets for limiting tumor 
cell progression. Epidermal growth factor (EGF) receptor (EGFR)-mediated motility, present in 
both autocrine and paracrine modes in prostate carcinomas, requires de novo transcription to 
persist over times greater than a few hours. Therefore, we sought to define specific signalling 
pathways that directly alter cellular transcription. STAT3 (Signal Transducer and Activator of 
Transcription 3) is activated, as determined by electrophoretic motility shift assays, by EGFR in 
DU145 and PC3 human prostate carcinoma cells in addition to the motility model NR6 fibroblast 
cell line. Downregulation of STAT3 activity by antisense oligonucleotides or siRNA or 
expression of a dominant-negative construct limited cell motility as determined by an in vitro 
wound healing assay and invasiveness through a extracellular matrix barrier. The expression of 
constitutively activated STAT3 did not increase the migration, which indicates that STAT3 is 
necessary but not sufficient for EGFR-mediated migration. These findings suggest that STAT3 
signalling may be a new target for limiting prostate tumor cell invasion.  
The inhibition of STAT3 expression does not decrease the basal or EGFR mediated 
proliferation of cells studied in this project, NR6WT murine fibroblasts and DU145WT and PC3 
human prostate tumor cells. These results contrasted with many of the previous research from 
other groups suggesting a positive regulation of tumor cell proliferation from EGF and STAT3 
[186] [261] [277] [278] [279]. On the other hand, other publications demonstrated that EGF 
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suppresses tumor growth [280] [281], or has different results between tumor cells in vivo and in 
vitro [282]. The most likely explanations for my proliferation data is that these cell lines either 
do not require STAT3 for in vitro proliferation (possibly by the presence of redundant inductive 
pathways) or the level of STAT3 inhibition attained is insufficient for proliferation and survival 
suppression. We prefer this second explanation as the apoptosis studies suggest that lacking 
STAT3 predisposes to cell death. This latter explanation also would suggest that motility is the 
more sensitive to transcriptional perturbations, in line with the laboratory’s earlier findings [100]. 
In a microarray analysis of what transcription units are altered by EGF in a 
STAT3-dependent manner in NR6WT fibroblast cells, we found that the expression of 
motility-limiting VASP protein and the apoptosis nexus Caspase-3 were both down regulated 
upon EGF exposure. The microarray data were confirmed by preliminary immunoblot 
experiments.  
As recent study shows, Ena/VASP proteins antagonize capping protein to inhibit actin 
polymerization at barbed ends in vitro [172], which suggested that Ena/VASP proteins associate 
with actin filaments at or near the barbed end and protect them from being capped by capping 
protein. The depletion of Ena/VASP causes the lamellipodia to protrude more slowly but to 
persist longer, yielding a faster moving cell [153]. Immunoblot on NR6WT fibroblast cells 
showed the expression of VASP protein is inhibited by EGF 30 minutes after the EGF treatment 
and last for about 24 hours. After adding STAT 3 antisense or STAT 3 siRNA, the expression of 
VASP goes back to normal level. This result supports the previous finding in microarray. Since 
EGF suppresses VASP expression, it is quite reasonable to ask in future studies if STAT3 plays a 
role in the VASP regulated-aspects of cell motility.  
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Further experiments showed that EGF could suppress VASP expression in DU145WT 
and PC3 human prostate tumor cells, though not as significantly as in NR6WT fibroblast cells. 
The reason could be high autocrine level of EGF in those cancer cells. 
Caspase-3 plays an essential role in the process of apoptosis as an executor of the caspase 
cascade. Recent publications demonstrated decreased caspase-3 level in various human tumor 
cells, which suggests the dire pathology of losing its effect on apoptosis; overcoming the 
inhibition of caspase-3-induced apoptosis in tumor cells and have little toxicity on normal cells 
[259]. My preliminary data from microarray and immunoblot sheds some light on the 
relationship between EGF/STAT 3 pathway and caspase-3. In sum, EGF can inhibit the 
activation and expression of caspase-3, which save the cells from apoptosis, while STAT 3 
siRNA overcomes the effect and make the cells vulnerable to apoptosis inducer. More 
experiments to focus on the EGF/STAT 3/caspase-3 apoptosis regulation pathway are ongoing. 
As a conclusion, the model that emerges is one in which STAT3 signaling downstream 
from EGFR is required for persistent cell motility and invasion, and that partial abrogation of this 
pathway hinders this tumor progression. Only more extensive abrogation of STAT3 signalling 
compromises carcinoma cell survival and proliferation. Thus, STAT3 inhibition, even if 
suboptimal, would slow tumor progression. 
6.2 SPECULATION 
There are still many questions about the EGF/STAT3 signalling pathway and its branches 
in human prostate cancer. One of the most crucial questions is the role STAT3 plays in the 
prostate tumor in vivo. Previous data showed aberrant STAT3 expression in many cancers 
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including prostate, as described in the introduction, and STAT3 activation is required for the 
proliferation of many cancer cell lines; though my in vitro proliferation data did not find such a 
connection in DU145WT and PC3 prostate tumor cells. Considering the complexity of signal 
transduction pathways in vivo, it is too early to say that STAT3 does not related to prostate tumor 
growth. At least, an in vivo assessment is necessary for determining this discrepancy.  
Early embryonic death in STAT3 knockout mice indicated that STAT3 is essential for 
early embryonic development [283]. Unforunately, this also excludes the possibility of adult 
STAT3-/- mice in which to induce de novo prostate tumor formation; crossbreeding with the 
TRAMP mice would be an example. The attempt of getting STAT3 dominant negative mutants 
in DU145WT prostate cancer cells was also performed as in NR6WT fibroblasts. Unfortunately, 
there were no stable clones survived from transfection and the following selection. The most 
likely explanation is that STAT3 is critical to the survival or viability of this cell line, and that 
the dominant negative was more efficient at downregulating STAT3 function than siRNA or 
antisense; these were only partially abrogating at best. A second possibility is that the STAT3 
DN also inhibited the functioning of other STAT isoforms through heterodimerization. The 
high-level background expression of STAT3 dominant negative even in the absence of 
dexamethasone may also contribute to this fatal result. To overcome the toxicity, I am planning 
an alternatively induced STAT3 mutant to avoid the highest levels of STAT3 signaling blockade. 
The lethality of STAT3 dominant negative expressing DU145WT human prostate cancer 
cells also attracts my attention to the cell death. Combined with previous microarray data, an 
EGF-STAT3-Caspase-3 signalling pathway emerged. Caspase-3 is a pivotal executor of 
apoptosis and the crosslink of the two main apoptosis pathways. Both Caspase-8 activated by the 
death receptor pathway and Caspase-9 activated by the mitochondria pathway will cleave 
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pro-Caspase-3 to then activate the downstream proteins to finish the program cell death. I used 
TNF-α to stimulate and activate the death receptor pathway of apoptosis, which can be 
suppressed by EGF and recovered by STAT3 abrogation by siRNA. Cisplatin is another 
apoptosis inducer, which initiates the mitochondria pathway by binding to the DNA of target 
cells [284]. It was also used in the experiment and obtained similar data. Those results suggested 
a critical role for STAT3 in apoptosis. Many other experiments are needed to confirm that 
EGF/STAT3 signaling pathway is involved in Caspase-3 regulation. For example, the 
measurement of Caspase-3 activity on its substrate with or without STAT3, is an essential 
complement for previous microarray and immunoblot data. I also need some other method like 
flow assay to check the cell apoptosis besides Annexing-V staining. 
The next step of studying STAT3 signaling in apoptosis would be the define of the whole 
signal transduction pathway. The intersection of STAT3 target genes and apoptosis related genes 
offers me a promising lode to mine. A well known such protein is BCL-XL [208]: increased 
expression of BCL-XL, an anti-apoptotic BCL-2 family gene, is dependent on constitutively 
activated STAT3. 
Since the STAT3 is a transcription factor, questions will be asked on how STAT3 
regulates the expression of those genes involved in apoptosis. From previous publications, it 
looks like STAT3 performs its mission by activating the expression of anti-apoptosis genes. Is 
the activation from direct STAT3 binding on the target DNA sequence, or from indirect 
mechanisms? Is the STAT3 activation also suppress some pro-apoptosis genes, such as Caspase 
3 herein? This was one of the unexpected aspects of the microarray, that STAT3 signaling 
appeared to repress gene transcription. As STAT3 is generally considered a transcription induced 
and not repressor, the question is whether this repression is direct by STAT3 or secondary to 
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STAT3 induction of a transcription repressor. The answer of those questions will be found in a 
more detailed study on the molecular level. 
While my findings reported herein suggest a molecular basis for the STAT3 dependence 
of EGFR-mediated prostate tumor progression, many more questions have been raised than 
answered. I hope that others can find value in addressing these issues. 
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7.0  ABBREVIATIONS 
ABL Abelson Leukemia Protein 
Arp Actin-related protein 
ATP Adenosine triphosphate 
BAD Bcl Associated Death promoter 
BAX BCL-2 Associated X protein 
BCL-2 B-Cell Lymphoma 2 
DAG Diacylglycerol 
DFF DNA fragmentation factor 
DHT Dihydrotestosterone 
EGF Epidermal Growth Factor 
eGFP Enhanced Green Fluorescent Protein 
EGFR Epidermal Growth Factor Receptor 
EMSA Electrophoretic Mobility Shift Assay 
Ena Enabled 
ERK Extracellular Signal-Regulated Kinase 
EVH Ena-VASP-Homology 
EVL Ena-VASP like 
FBS Fetal Bovine Sera 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
HGF Hepatocyte Growth Factor 
IFN Interferon 
IHC Immunohistochemistry 
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IL-6 Interleukin-6 
IP3  Inositol 1,4,5-triphosphate 
JAK Jauns Kinase 
MAPK Mitogen-Activated Protein Kinase 
Mena Mammalian Enabled 
PARP Poly ADP-Ribose Polymerase 
PCR Polymerase Chain Reaction 
PIP2  Phosphatidyl Inositol 3,4-bisphosphate 
PKC Protein Kinase C 
PLC-γ Phospholipase C-γ 
PSA  Prostate Specific Antigen 
RNAi RNA Interference 
SH2 SRC Homology 2 
STAT Signal Transducer and Activator of Transcription 
TAD Transcriptional Activation Domain 
TGF-α Transformation Growth Factor-α 
TKI Tyrosine Kinase Inhibitor 
TNF Tumor Necrosis Factor 
VASP Vasodilator-stimulated phosphoprotein 
VEGF Vascular Endothelial Growth Factor 
XIAP X-Chromosome-Linked Inhibitor Of Apoptosis Protein 
ZBP Zipcode Binding Protein 
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